Skip to main content
PLOS Computational Biology logoLink to PLOS Computational Biology
. 2022 Apr 11;18(4):e1010013. doi: 10.1371/journal.pcbi.1010013

Are transient protein-protein interactions more dispensable?

Mohamed Ali Ghadie 1, Yu Xia 1,*
Editor: Ozlem Keskin2
PMCID: PMC9000134  PMID: 35404956

Abstract

Protein-protein interactions (PPIs) are key drivers of cell function and evolution. While it is widely assumed that most permanent PPIs are important for cellular function, it remains unclear whether transient PPIs are equally important. Here, we estimate and compare dispensable content among transient PPIs and permanent PPIs in human. Starting with a human reference interactome mapped by experiments, we construct a human structural interactome by building three-dimensional structural models for PPIs, and then distinguish transient PPIs from permanent PPIs using several structural and biophysical properties. We map common mutations from healthy individuals and disease-causing mutations onto the structural interactome, and perform structure-based calculations of the probabilities for common mutations (assumed to be neutral) and disease mutations (assumed to be mildly deleterious) to disrupt transient PPIs and permanent PPIs. Using Bayes’ theorem we estimate that a similarly small fraction (<~20%) of both transient and permanent PPIs are completely dispensable, i.e., effectively neutral upon disruption. Hence, transient and permanent interactions are subject to similarly strong selective constraints in the human interactome.

Author summary

All cellular functions are driven by interactions between different biomolecules in the cell. Among these interactions are protein-protein interactions, abbreviated as PPIs, in which two proteins physically bind to each other to perform a specific molecular function. PPIs are often divided into two categories: transient PPIs where two proteins bind to each other only for a short time and then break apart, and permanent PPIs where two proteins bind to each other permanently thus forming a permanent protein complex. Considering their permanent nature, it is generally assumed that permanent PPIs are important for cellular function, whereas it remains unclear whether transient PPIs are equally important. Here, we estimate the fractions of transient PPIs and permanent PPIs in human that can be removed from the cell without harming human fitness. We do this by constructing three-dimensional structural models for PPIs which allow us to predict the probabilities for disease-causing mutations and non-disease mutations from healthy individuals to disrupt transient PPIs and permanent PPIs. Using these probabilities, we estimate that similar to permanent PPIs only a small fraction of transient PPIs (<~20%) can be disrupted without harming fitness, indicating that most transient and permanent PPIs are important for cellular function in human.

Introduction

Protein-protein interactions (PPIs) implement thousands of functions at the molecular level, taking part in almost every biological process in the cell. Hence, the collective network of PPIs, commonly known as the interactome network, has been imperative for our understanding of cell function [1,2], disease [37], and evolution [811], especially when combined with protein structural information [1221]. Nonetheless, PPIs across the interactome network are very diverse in their structural, biophysical and spatiotemporal properties [2224]. Based on their binding patterns across time and space, PPIs are divided into two categories: transient PPIs and permanent PPIs [22,23]. These binding patterns are largely controlled by the strength of interaction as well as co-expression of interaction partners [2527]. A PPI is transient in time if the two interaction partners form a weak interaction only for a short period of time and then break apart [22,23,27]. On the other hand, a PPI is permanent in time if the two interaction partners form a strong interaction that continues to exist without breaking apart thus forming a permanent protein complex [22,27]. PPIs can also be transient or permanent in space [28]. A PPI is permanent in space if the two interaction partners always co-express to form stoichiometric complexes in the same tissues or cell types, and transient otherwise [28,29]. While systems biology studies typically rely on the assumption that most PPIs in human are important for cellular function [2,5,30,31], we recently estimated that indeed only <~20% of the human interactome is completely dispensable, i.e., effectively neutral upon disruption by mutation [20]. Completely dispensable PPIs are those PPIs that are disrupted in the presence of a mutation at the binding interface, i.e., they are completely eliminated from the interactome as a result of mutation, however their elimination from the interactome has no measurable deleterious impact on organismal fitness [20]. These completely dispensable PPIs are different than other PPIs that are robust to the presence of mutations at the interface hence are not eliminated from the interactome as a result of mutation [9,11,32]. However, our estimate of dispensable content in the human interactome represents an average over the entire interactome. It remains an open question whether transient PPIs have more dispensable content than other permanent PPIs [3335].

The question of how important transient PPIs are to cellular function is crucial to our understanding of cell systems biology and human disease [5,30,31]. In the absence of any quantitative model for measuring the importance of transient PPIs, our judgement relies heavily on different studies leading to diverging conclusions. On the one hand, many transient PPIs have been found to play important roles in defining the structure of interactome networks, such as regulating interactome modularity [26,27] and guiding the formation of obligate protein complexes [36,37]. Other transient PPIs are known to participate in multiple cellular pathways and biochemical processes, including secretory pathways [38], signal transduction [3941], immune response [42], chaperone-guided protein folding [43,44], apoptosis [45], and tumor suppression [46]. While these studies show that many transient PPIs play important roles in cellular function and human disease, it remains unclear whether this observed functional significance generalizes to most transient PPIs. On the other hand, transient PPIs differ from permanent PPIs in their structural composition and binding dynamics [23,27,47]. They tend to occur among certain protein hubs, known as “date hubs”, which interact with multiple partners in a mutually exclusive manner using the same binding interface [12,26]. This behaviour is contrary to that of permanent PPIs which tend to occur among a different type of protein hubs, known as “party hubs”, which interact with multiple partners simultaneously using multiple binding interfaces [12,26]. Mutually exclusive transient PPIs are often mediated through short linear motifs that typically occur in intrinsically disordered regions [27,48,49]. These binding motifs tend to be smaller in surface area and contain less hydrophobic residues than interfaces of permanent PPIs, thus they bind with weaker affinities [27]. Linear motifs also evolve very rapidly [27,49], contributing in part to the higher rate of rewiring among transient PPIs compared to permanent PPIs [35,5052]. Indeed, empirical studies in phospho-proteomics and molecular evolution estimate that as much as ~65% of transient phosphorylation sites in yeast are unconstrained under evolution and may have no important function [33,34].

Detecting transient PPIs in experiments and through computational predictions is very challenging [23,47,53]. With different limitations and biases associated with experimental techniques for detecting PPIs [54,55], large-scale datasets of transient PPIs are currently not available. However, databases that curate PPI sequence and structural information such as linear motifs [56,57], domain-motif interactions [58], domain-domain interactions [59], three-dimensional protein structures [60], and binding affinities [61] from both experimental and computational studies can be used to predict transient and permanent PPIs. Some studies have used PPI binding affinity measurements from experiments to identify transient and permanent interactions [61,62]. The scope of these studies is limited by the small number of PPIs with affinity data available from experiments. Computational studies have used interface structural information [12,63], protein sequence information [64] and machine learning models [65,66] to predict transient and permanent PPIs. Other studies made use of gene expression data which does not rely on experimentally-solved protein structures [25,67]. Since the criteria and information that were used to detect transient interactions vary among these studies, each study has its own biases and sources of error. Moreover, with the large increase in PPI datasets recently mapped by experiments in human [68,69], and given the difficulty in identifying transient PPIs in experiments, there is a great need for new computational efforts to accurately classify transient and permanent interactions in these new datasets, taking into account different structural and biophysical properties that distinguish transient PPIs from permanent PPIs.

Here, in an effort to answer the long-standing question of the overall importance of transient PPIs, we provide a quantitative measure of their importance and compare them with permanent PPIs by estimating dispensable content among both types of PPIs, using the same procedure we developed before to estimate dispensable content in the overall human interactome [11,20]. Starting with a high-quality human reference interactome mapped by experiments, we apply homology modelling similar to [20] to construct a high-resolution three-dimensional (3D) human structural interactome with PPI binding interfaces annotated at the residue level (Fig 1A). This structural interactome is much larger than our previously constructed structural interactome in [20]. Next, we label each PPI in the structural interactome as either transient or permanent based on different structural, biophysical and spatiotemporal properties (Fig 1A). We map common mutations from healthy individuals as well as Mendelian disease-causing mutations onto the human structural interactome and perform structure-based calculations similar to [20] to predict the edgotype [70] for each mutation, i.e., the precise pattern of PPI perturbations as a result of each mutation. Unlike in [20], here the edgotype of a mutation is defined separately for each group of PPIs, transient and permanent. Finally, we integrate our edgotype predictions into the same Bayesian framework we used in [20] and calculate the fraction of PPIs that are completely dispensable, i.e., effectively neutral upon disruption by mutation, among each group of PPIs (Fig 1B). Overall, we estimate that only <~20% of transient PPIs are completely dispensable, and the remaining are at least mildly deleterious upon disruption. We also estimate that <~20% of permanent PPIs are completely dispensable. These two estimates are comparable to our estimate of dispensable content calculated over all PPIs in the interactome network, using both predicted mutation edgotypes as well as mutation edgotypes obtained from experiments [4]. Our results reveal that, similar to permanent PPIs, most transient PPIs (>~80%) are important to cellular function hence deleterious upon disruption. Our results also suggest that transient and permanent interactions are subject to similarly strong selective constraints in the human interactome.

Fig 1. Computational pipeline for structure-based calculation of dispensable PPI content.

Fig 1

(a) Construction of the human structural interactome and subsequent classification of transient PPIs and permanent PPIs using structural, biophysical and spatiotemporal properties. (b) Structure-based prediction of PPI perturbations by missense mutations, and subsequent calculation of dispensable PPI content.

Results

Structure-based prediction of mutation edgotypes

We obtained two high-quality human reference interactomes that were mapped by experiments: the HuRI interactome consisting of PPIs identified most recently in yeast two-hybrid (Y2H) screens [68], and the literature-curated interactome consisting of PPIs reported by at least two independent experiments in the IntAct database [71]. From each reference interactome, we constructed a human structural interactome by building 3D structural models for PPIs using homology modelling based on experimentally determined structural templates in PDB [60] (Fig 1A). As a result, we obtained two high-resolution human structural interactomes with PPI binding interfaces annotated at the residue level: the Y2H structural interactome (Y2H-SI) consisting of 1,916 PPIs among 1,468 proteins (S1A Data), and the literature-derived structural interactome (Lit-SI) consisting of 4,676 PPIs among 3,445 proteins (S1B Data). These two structural interactomes are much larger than the structural interactomes we had previously constructed in [20]. Y2H-SI which was derived in this study from the recent HuRI dataset is 4 times larger in number of PPIs than the Y2H structural interactome in [20], which was derived from the much smaller HI-II-14 dataset [72]. In addition, Lit-SI in this study is also 1.4 times larger in number of PPIs than the literature-derived structural interactome in [20].

Next, we mapped Mendelian disease-causing missense mutations from ClinVar [73] and common missense mutations not associated with any disease from dbSNP [74] onto the two human structural interactomes, Y2H-SI and Lit-SI (Fig 1B). As a result, we obtained 348 disease mutations and 1,080 common mutations in Y2H-SI (S2A and S2B Data), as well as 1,572 disease mutations and 2,867 common mutations in Lit-SI (S2C and S2D Data). These mutations cover ~39% of proteins in Y2H-SI and ~42% of proteins in Lit-SI, thus spanning a significant part of the human structural interactome. In addition, these results represent a 2.74-fold and 1.34-fold increase in the number of mutations that were successfully mapped onto Y2H-SI and Lit-SI, respectively, compared to our previous results in [20].

Using our structural interactomes, we performed structure-based calculations to predict the edgotype [70] for each mutation, i.e., the precise pattern of interactome perturbations created by each mutation (Fig 1B). The edgotype of a mutation is edgetic if it disrupts PPIs by disrupting a specific binding interface, quasi-null if it disrupts all PPIs by disrupting overall protein stability, or quasi-wild-type if it does not disrupt any PPI [4]. We predict that at a mutation edgetically disrupts a PPI if and only if the mutation occurs on the interface mediating that PPI and causes a change in PPI binding free energy (ΔΔG) larger than 0.5 kcal/mol (S2 Data), as calculated on the PPI structural model using FoldX [75] (S3 Data).

Dispensable content among weak transient PPIs and strong permanent PPIs

One biophysical property that distinguishes transient PPIs from permanent PPIs is the strength of interaction. While transient PPIs tend to form weak molecular interactions that are easily broken apart, permanent PPIs tend to form stronger interactions that are harder to break [27]. Thus, we estimated dispensable content among weak transient PPIs as well as strong permanent PPIs in both structural interactomes Y2H-SI and Lit-SI. We consider a PPI to be weak if it has a binding free energy ΔG ≥ -25 kcal/mol as calculated by FoldX on the PPI structural template, otherwise we consider the PPI to be strong (S4 Data). According to this definition, 57% of PPIs in Y2H-SI and 66% of PPIs in Lit-SI are considered to be weak interactions (S5 Data).

We first calculated dispensable content among weak transient PPIs and strong permanent PPIs in Y2H-SI, using the Bayesian framework we had previously developed [11,20] and describe here in the Methods section. We assume that mutations are either effectively neutral (similar to synonymous mutations), mildly deleterious, or strongly detrimental (similar to nonsense mutations that introduce premature stop codons). In addition, we assume that common mutations from healthy individuals are effectively neutral, that Mendelian disease-causing mutations are mildly deleterious on average, and that strongly detrimental mutations are predominantly quasi-null (i.e., disrupt overall protein stability) rather than edgetic. Here, it is important to make a clear distinction between a mutation’s fitness effect on the one hand and its impact on the interactome network on the other hand. Both effectively neutral mutations and deleterious mutations may or may not disrupt PPIs, hence they both may or may not be edgetic.

Therefore, from our edgotype predictions in Y2H-SI shown in Table 1, we obtained the probabilities for effectively neutral mutations (N) to edgetically disrupt weak transient PPIs (T): P(T|N) = 3/1080 = 0.3%, and to edgetically disrupt strong permanent PPIs (P): P(P|N) = 13/1080 = 1.2% (Fig 2A and Table 2). We also obtained the probabilities for mildly deleterious mutations (M) to edgetically disrupt weak transient PPIs (T): P(T|M) = 7/348 = 2%, and to edgetically disrupt strong permanent PPIs (P): P(P|M) = 36/348 = 10.3% (Fig 2A and Table 2). From these probabilities, we found that the propensity for neutral mutations to disrupt weak transient PPIs relative to mildly deleterious mutations is as low as that among strong permanent PPIs (0.15 for transient PPIs, and 0.12 for permanent PPIs) (Table 2). This similar low enrichment of PPI disruptions by neutral mutations among transient and permanent PPIs already suggests that both types of PPIs are as likely to be effectively neutral upon disruption by mutation.

Table 1. Mutation edgotype data obtained from predictions.

Number of common mutations and disease mutations that edgetically disrupt transient and permanent PPIs defined by different structural, biophysical and spatiotemporal properties in the two human structural interactomes Y2H-SI and Lit-SI.

PPI properties Common mutations Disease mutations
Transient PPIs Permanent PPIs Expression data SI Total Disrupt transient PPIs Disrupt permanent PPIs Total Disrupt transient PPIs Disrupt permanent PPIs
Weak Strong Y2H 1,080 3 13 348 7 36
Lit 2,867 27 29 1,572 51 68
Transient in time Permanent in time Time-course (GEO) Y2H 1,080 7 9 347 18 24
Lit 2,867 16 40 1,571 57 61
Transient in space Permanent in space Tissue (Illumina) Y2H 1,075 4 7 336 12 19
Lit 2,859 19 29 1,563 61 49
Tissue (Fantom5) Y2H 1,080 3 13 345 23 17
Lit 2,862 19 32 1,570 57 60
Unbalanced over time Balanced over time Time-course (GEO) Y2H 1,080 1 15 347 8 34
Lit 2,867 12 44 1,570 32 85
Unbalanced over space Balanced over space Tissue (Illumina) Y2H 1,080 11 5 343 21 17
Lit 2,866 32 23 1,567 58 56
Tissue (Fantom5) Y2H 1,080 6 10 344 22 17
Lit 2,862 22 29 1,568 48 67
1–4 mutually exclusives No mutually exclusives Y2H 1,079 4 2 348 24 8
Lit 2,865 30 10 1,566 50 34
≥5 mutually exclusives Y2H 1,079 9 348 11
Lit 2,865 14 1,566 29

Fig 2. Dispensable content among weak transient PPIs and strong permanent PPIs.

Fig 2

(a) Fractions of common mutations and disease mutations that edgetically disrupt weak transient PPIs and strong permanent PPIs in the two human structural interactomes Y2H-SI and Lit-SI. (b) Fractions of common mutations and disease mutations that edgetically disrupt any PPI in the human interactome as determined by experiments of Sahni et al. [4]. (c) Dispensable content among weak transient PPIs, strong permanent PPIs, and all PPIs in human calculated using predicted mutation edgotypes in the two human structural interactomes Y2H-SI and Lit-SI, as well as using mutation edgotypes determined by experiments of Sahni et al. [4]. Error bars represent 95% confidence intervals.

Table 2. Dispensable content among transient and permanent PPIs.

PPI properties Transient PPIs Permanent PPIs
Transient PPIs Permanent PPIs Expression data SI P(T|N) P(T|M) P(T|N)P(T|M) P(N|T) P(P|N) P(P|M) P(P|N)P(P|M) P(N|P)
Weak Strong Y2H 0.3 2.0 0.15 6.6 1.2 10.3 0.12 5.6
Lit 0.9 3.2 0.28 12.9 1.0 4.3 0.23 10.6
Transient in time Permanent in time Time-course (GEO) Y2H 0.6 5.2 0.12 6 0.8 6.9 0.12 5.8
Lit 0.6 3.6 0.17 7.3 1.4 3.9 0.36 15.5
Transient in space Permanent in space Tissue (Illumina) Y2H 0.4 3.6 0.11 5 0.7 5.7 0.12 5.5
Lit 0.7 3.9 0.18 8 1.0 3.1 0.32 14.2
Tissue (Fantom5) Y2H 0.3 6.7 0.04 2.1 1.2 4.9 0.24 11.1
Lit 0.7 3.6 0.19 8.5 1.1 3.8 0.29 13
Unbalanced over time Balanced over time Time-course (GEO) Y2H 0.1 2.3 0.04 2 1.4 9.8 0.14 6.7
Lit 0.4 2.0 0.20 9.5 1.5 5.4 0.28 12.6
Unbalanced over space Balanced over space Tissue (Illumina) Y2H 1.0 6.1 0.16 7.8 0.5 5.0 0.10 4.5
Lit 1.1 3.7 0.30 13.3 0.8 3.6 0.22 10.3
Tissue (Fantom5) Y2H 0.6 6.4 0.09 4.2 0.9 4.9 0.18 8.7
Lit 0.8 3.1 0.26 11.3 1.0 4.3 0.23 10.8
1–4 mutually exclusives No mutually exclusives Y2H 0.4 6.9 0.06 2.7 0.2 2.3 0.09 4.0
Lit 1.0 3.2 0.31 14.3 0.3 2.2 0.14 7.6
≥5 mutually exclusives Y2H 0.8 3.2 0.25 11.9
Lit 0.5 1.9 0.26 11.9

Edgotype probabilities for neutral and mildly deleterious mutations calculated directly from edgotype numbers in Table 1, assuming that common mutations are effectively neutral (N) and that disease mutations are mildly deleterious (M) on average. The resulting dispensable contents P(N|T) and P(N|P) among both transient (T) and permanent (P) PPIs were calculated using Bayes’ theorem. Columns represent the following, SI: structural interactome, P(T|N): probability (%) for neutral mutations (N) to edgetically disrupt transient PPIs (T), P(T|M): probability (%) for mildly deleterious mutations (M) to edgetically disrupt transient PPIs (T), P(N|T): dispensable content among transient PPIs defined as the probability (%) for transient PPIs to be effectively neutral upon disruption, P(P|N): probability (%) for neutral mutations (N) to edgetically disrupt permanent PPIs (P), P(P|M): probability (%) for mildly deleterious mutations (M) to edgetically disrupt permanent PPIs (P), P(N|P): dispensable content among permanent PPIs defined as the probability (%) for permanent PPIs to be effectively neutral upon disruption.

Next, we obtained from Kryukov et al. [76] the probabilities for new missense mutations to be effectively neutral (N), mildly deleterious (M), or strongly detrimental (S): P(N) = 27%, P(M) = 53%, P(S) = 20%. We then integrated these numbers into Eq 1 in the Methods section to calculate the probability for a new missense mutation to edgetically disrupt a weak transient PPI (T):

P(T)=P(T|N)P(N)+P(T|M)P(M)+P(T|S)P(S)=1.1%

where P(T|S) is assumed to be approximately 0. Finally, using Bayes’ theorem (Eq 2 in Methods), we calculated the probability for a missense mutation that edgetically disrupts a weak transient PPI (T) to be effectively neutral (N):

P(N|T)=P(T|N)P(N)P(T)=6.6%

Therefore, since most mutations that edgetically disrupt weak transient PPIs in Y2H-SI (60%) disrupt only one PPI, we estimated that ~7% of weak transient PPIs in human are completely dispensable, i.e., effectively neutral upon disruption, with a 95% confidence interval of ~2–21% (Fig 2C and Table 2).

We applied the same procedure again to calculate dispensable content among strong permanent PPIs in Y2H-SI. From our edgotype predictions shown in Table 1, we obtained the probability for neutral mutations (N) to edgetically disrupt strong permanent PPIs (P): P(P|N) = 1.2%, and the probability for mildly deleterious mutations (M) to edgetically disrupt strong permanent PPIs (P): P(P|M) = 10.3% (Fig 2A and Table 2). We then integrated these edgotype probabilities into Eq 1 in the Methods section to calculate the probability for a new missense mutation to edgetically disrupt a strong permanent PPI (P):

P(P)=P(P|N)P(N)+P(P|M)P(M)+P(P|S)P(S)=5.8%

where P(P|S) is assumed to be approximately 0. Using Bayes’ theorem again (Eq 2 in Methods), we calculated the probability for a missense mutation that edgetically disrupts a strong permanent PPI (P) to be effectively neutral (N):

P(N|P)=P(P|N)P(N)P(P)=5.6%

Thus, we estimated that ~6% of strong permanent PPIs in human are completely dispensable with a 95% confidence interval of ~3–10% (Fig 2C and Table 2).

Finally, we repeated the same calculations using edgotype predictions in Lit-SI shown in Table 1. Similar to Y2H-SI, we found a similar enrichment of PPI disruptions by neutral mutations compared to mildly deleterious mutations among both weak transient PPIs and strong permanent PPIs (Fig 2A and Table 2). Thus, we estimated that ~13% of weak transient PPIs in Lit-SI are completely dispensable with a 95% confidence interval of ~9–19% (Fig 2C and Table 2), and that ~11% of strong permanent PPIs in Lit-SI are completely dispensable with a 95% confidence interval of ~7–15% (Fig 2C and Table 2). Overall, our calculations reveal that dispensable content among both types of PPIs in human, transient and permanent, is below ~20%. This estimate is comparable to our estimates of dispensable content calculated among all PPIs together using predicted mutation edgotypes in Y2H-SI and Lit-SI as well as mutation edgotypes obtained from experiments [4] (Fig 2C).

Dispensable content among temporally transient PPIs

A second property that distinguishes transient PPIs from permanent PPIs is the time duration of interaction. A PPI is transient in time if the interaction partners bind to each other only for a short period of time and then break apart. On the other hand, a PPI is permanent in time if the interaction partners bind to each other without breaking apart thus forming a permanent protein complex [27] (Fig 3A). Date hubs in particular bind to different partners at different points in time through short-term transient interactions, whereas party hubs bind to different partners at the same time through permanent interactions [12,27]. Thus, transient interaction partners show much less co-expression over time than permanent interaction partners [2527].

Fig 3. Dispensable content among transient and permanent PPIs in time and space.

Fig 3

(a) Graphical description of temporally transient PPIs and temporally permanent PPIs. (b) Edgotype predictions (left) and dispensable content (right) among temporally transient PPIs and temporally permanent PPIs in the two human structural interactomes, Y2H-SI and Lit-SI. Transient and permanent PPIs were identified based on time-course co-expression of interaction partners derived from the Gene Expression Omnibus data. (c) Graphical description of spatially transient PPIs and spatially permanent PPIs. (d) Edgotype predictions (left) and dispensable content (right) among spatially transient PPIs and spatially permanent PPIs in the two human structural interactomes, Y2H-SI and Lit-SI. Transient and permanent PPIs were identified based on tissue co-expression of interaction partners derived from the Illumina Body Map 2.0 project data. (e) Edgotype predictions (left) and dispensable content (right) among spatially transient PPIs and spatially permanent PPIs in the two human structural interactomes, Y2H-SI and Lit-SI. Transient and permanent PPIs were identified based on correlations in gene promoter activity levels associated with interaction partners derived from the Fantom5 project data. All error bars represent 95% confidence intervals.

Here, we estimated dispensable content among PPIs that are transient in time as well as PPIs that are permanent in time in human. First, we quantified gene time-course expression levels in human from 63 experiments reported in the Gene Expression Omnibus (GEO) [77], with expression levels measured over at least 5 different time points in each experiment (S6A Data). Next, we distinguished transient PPIs from permanent PPIs by measuring the temporal co-expression of interaction partners using Pearson’s correlation coefficient of their gene expression profiles reported in each experiment (S7A and S7B Data). We consider a PPI to be transient in time if it is transient in the majority of experiments, where a PPI is transient in an experiment if the co-expression of its interaction partners in that experiment is less than the median co-expression of all interaction partners across all experiments (0.1 in Y2H-SI, and 0.11 in Lit-SI). According to this definition, 43% of PPIs in Y2H-SI and 43% of PPIs in Lit-SI are considered to be transient in time (S5 Data).

Given these PPI classifications, as in the previous section, we obtained from our edgotype predictions in Table 1 the probabilities for effectively neutral mutations and mildly deleterious mutations to edgetically disrupt temporally transient PPIs as well as temporally permanent PPIs in both structural interactomes, Y2H-SI and Lit-SI (Fig 3B and Table 2). Here, we also found a similarly low enrichment of PPI disruptions by neutral mutations compared to mildly deleterious mutations among both temporally transient PPIs and temporally permanent PPIs (Table 2), suggesting again that transient PPIs are as likely to be dispensable as permanent PPIs. Next, we integrated these edgotype probabilities again into our Bayesian framework described in the Methods section to calculate dispensable content among temporally transient PPIs as well as temporally permanent PPIs. As a result, we estimated that <~20% of temporally transient PPIs are completely dispensable, i.e., effectively neutral upon disruption, in both interactomes Y2H-SI and Lit-SI (Fig 3B and Table 2). We also estimated that <~20% of temporally permanent PPIs are completely dispensable in both interactomes (Fig 3B and Table 2).

Dispensable content among spatially transient PPIs

In addition to being transient or permanent in time, PPIs can also be transient or permanent in space. A PPI is permanent in space if the two interaction partners always co-express to form stoichiometric complexes in the same tissues or cell types, and transient if otherwise [28] (Fig 3C). Here, we estimated dispensable content among PPIs that are transient in space as well as PPIs that are permanent in space in human. First, we quantified gene expression levels in 16 human body tissues using RNA-Seq gene expression data from the Illumina Body Map 2.0 project [78] (S6B Data). Next, we distinguished transient PPIs from permanent PPIs by measuring tissue co-expression of interaction partners using Pearson’s correlation coefficient of their gene expression profiles (S7C and S7D Data). We consider a PPI to be transient in space if the co-expression of its interaction partners is less than the median co-expression of all interaction partners in the structural interactome (0.39 in Y2H-SI, and 0.45 in Lit-SI), otherwise we consider the PPI to be permanent in space. According to this definition, 49% of PPIs in Y2H-SI and 50% of PPIs in Lit-SI are considered to be transient in space (S5 Data).

Given these PPI classifications, as in previous sections, we obtained from our edgotype predictions in Table 1 the probabilities for effectively neutral mutations and mildly deleterious mutations to edgetically disrupt spatially transient PPIs as well as spatially permanent PPIs in both structural interactomes, Y2H-SI and Lit-SI (Fig 3D and Table 2). Again, we found a similarly low enrichment of PPI disruptions by neutral mutations compared to mildly deleterious mutations among both spatially transient PPIs and spatially permanent PPIs (Table 2). Using these edgotype probabilities, we applied our Bayesian framework described in the Methods section again to estimate dispensable content among spatially transient PPIs and spatially permanent PPIs. As a result, we estimated that <~20% of spatially transient PPIs are completely dispensable, i.e., effectively neutral upon disruption, in both interactomes Y2H-SI and Lit-SI (Fig 3D and Table 2). We also estimated that <~20% of spatially permanent PPIs are completely dispensable in both interactomes (Fig 3D and Table 2).

In addition, we repeated our calculations again, this time distinguishing spatially transient PPIs from spatially permanent PPIs based on correlations in gene promoter activity associated with interacting proteins, as measured by the Fantom5 project in 183 human body tissue samples [79] (S6C Data). Using this promoter-level data, we consider a PPI to be transient in space if the correlation in gene promoter activity associated with its interaction partners is less than the median correlation of all interaction partners in the structural interactome (0.16 in Y2H-SI, and 0.22 in Lit-SI), otherwise we consider the PPI to be permanent in space (S7C and S7D Data). According to this definition, 50% of PPIs in Y2H-SI and 49% of PPIs in Lit-SI are considered to be transient in space (S5 Data). Given these new PPI classifications and associated edgotype predictions shown in Table 1, we also estimated that <~20% of spatially transient PPIs are completely dispensable in both interactomes Y2H-SI and Lit-SI (Fig 3E and Table 2). Similarly, we estimated that <~20% of spatially permanent PPIs are completely dispensable in both interactomes (Fig 3E and Table 2).

Dispensable content among unbalanced PPIs

A fourth property that distinguishes transient PPIs from permanent PPIs is the quantitative stoichiometry of interaction [29]. While transient PPIs often involve date hubs interacting with multiple partners at different points in time [12,27], these multiple partners may often be multiple copies of the same protein [29]. Thus, unlike permanent interaction partners, transient interaction partners tend to have unbalanced ratios of abundance, with the hub protein having significantly lower expression levels than its interaction partners [29]. This unbalance in protein abundance may be observed across different points in time (Fig 4A) and/or across different tissues (Fig 4C).

Fig 4. Dispensable content among unbalanced and balanced PPIs over time and space.

Fig 4

(a) Graphical description of temporally balanced PPIs and temporally unbalanced PPIs. (b) Edgotype predictions (left) and dispensable content (right) among temporally balanced PPIs and temporally unbalanced PPIs in the two human structural interactomes, Y2H-SI and Lit-SI. Balanced and unbalanced PPIs were identified based on time-course expression levels of interaction partners derived from the Gene Expression Omnibus data. (c) Graphical illustration of spatially balanced PPIs and spatially unbalanced PPIs. (d) Edgotype predictions (left) and dispensable content (right) among spatially balanced PPIs and spatially unbalanced PPIs in the two human structural interactomes, Y2H-SI and Lit-SI. Balanced and unbalanced PPIs were identified based on tissue expression levels of interaction partners derived from the Illumina Body Map 2.0 project data. (e) Edgotype predictions (left) and dispensable content (right) among spatially balanced PPIs and spatially unbalanced PPIs in the two human structural interactomes, Y2H-SI and Lit-SI. Balanced and unbalanced PPIs were identified based on gene promoter activity levels associated with interaction partners derived from the Fantom5 project data. All error bars represent 95% confidence intervals.

Here, we estimated dispensable content among PPIs with unbalanced abundance among interaction partners as well as PPIs with balanced abundance among interaction partners, using time-course expression data as well as tissue-based expression data. First, we obtained gene time-course expression data in human from 63 experiments reported in the Gene Expression Omnibus (GEO) [77], with expression levels measured over at least 5 different time points in each experiment (S6A Data). Next, we calculated the log10 difference in expression levels for interaction partners at each time point in each experiment (S8 Data). We consider a PPI to be unbalanced if it is unbalanced in the majority of experiments, where a PPI is unbalanced in an experiment if the average of the absolute log10 difference in expression over time for its interaction partners is larger than the median value among all experiments for all interaction partners in the structural interactome (0.38 in Y2H-SI, and 0.40 in Lit-SI). According to this definition, 23% of PPIs in Y2H-SI and 26% of PPIs in Lit-SI are considered to be unbalanced over time (S5 Data).

Given these PPI classifications and our edgotype predictions in Table 1, we calculated the probabilities for effectively neutral mutations and mildly deleterious mutations to edgetically disrupt unbalanced PPIs as well as balanced PPIs in both structural interactomes, Y2H-SI and Lit-SI (Fig 4B and Table 2). As with our previous observations, we also found a similarly low enrichment of PPI disruptions by neutral mutations compared to mildly deleterious mutations among both unbalanced PPIs and balanced PPIs (Table 2). We integrated these probabilities into our Bayesian framework as in the previous sections and estimated that <~20% of unbalanced PPIs are completely dispensable, i.e., effectively neutral upon disruption, in both interactomes Y2H-SI and Lit-SI (Fig 4B and Table 2). We also estimated that <~20% of balanced PPIs are completely dispensable in both interactomes (Fig 4B and Table 2).

In addition, we also obtained gene expression levels in 16 human body tissues from the Illumina Body Map 2.0 project [78] (S6B Data), and calculated the log10 difference in expression levels for interaction partners across all tissues (S9A and S9B Data). Using this tissue-based expression data, we consider a PPI to be unbalanced if the average of the absolute log10 difference in expression across all tissues for its interaction partners is larger than the median value for all interaction partners in the structural interactome (0.63 in Y2H-SI, and 0.56 in Lit-SI), otherwise we consider the PPI to be balanced. According to this definition, 50% of PPIs in Y2H-SI and 50% of PPIs in Lit-SI are considered to be unbalanced over space (S5 Data). Given these PPI classifications and our edgotype predictions in Table 1, we also estimated that <~20% of both unbalanced PPIs and balanced PPIs are completely dispensable in both structural interactomes Y2H-SI and Lit-SI (Fig 4D and Table 2).

Finally, we repeated our predictions of PPI disruptions this time distinguishing balanced PPIs from unbalanced PPIs using gene promoter activity data associated with interaction partners, as measured by the Fantom5 project in 183 human body tissue samples [79] (S6C Data). Again, we consider a PPI to be unbalanced if the average of the absolute log10 difference in expression across all tissues for its interaction partners is larger than the median value for all interaction partners in the structural interactome (0.68 in Y2H-SI, and 0.59 in Lit-SI), otherwise we consider the PPI to be balanced (S9C and S9D Data). According to this definition, also 50% of PPIs in Y2H-SI and 50% of PPIs in Lit-SI are considered to be unbalanced over space (S5 Data). Given these PPI classifications and our edgotype predictions in Table 1, we also estimated that <~20% of both unbalanced PPIs and balanced PPIs are completely dispensable in both structural interactomes (Fig 4E and Table 2).

Dispensable content among mutually exclusive PPIs

At the structural level, one property underlying the transient or permanent nature of PPIs is the number of interaction partners targeting the same binding interface of a protein [12,27]. Date hubs use the same binding interface to carry out transient interactions with multiple partners in a mutually exclusive manner (Fig 5A). On the other hand, party hubs are able to form permanent interactions with multiple partners simultaneously using multiple interfaces (Fig 5A). Thus, we estimated dispensable content among three groups of PPIs: PPIs that do not share their binding interface with any other PPI, PPIs that share their binding interface in a mutually exclusive manner with 1 to 4 PPIs, and PPIs that share their binding interface in a mutually exclusive manner with 5 or more PPIs (S10 Data). In Y2H-SI, we found that 15% of PPIs do not share their binding interface with any other PPI, 42% share their binding interface with 1 to 4 mutually exclusive PPIs, and 43% share their binding interface with 5 or more mutually exclusive PPIs (S5A Data). In Lit-SI, we found that 16% of PPIs do not share their binding interface with any other PPI, 51% share their binding interface with 1 to 4 mutually exclusive PPIs, and 33% share their binding interface with 5 or more mutually exclusive PPIs (S5B Data).

Fig 5. Dispensable content among mutually exclusive and simultaneously possible PPIs.

Fig 5

(a) Graphical description of simultaneously possible PPIs mediated by a multi-interface protein and mutually exclusive PPIs mediated by a single-interface protein. (b) Edgotype predictions (left) and dispensable content (right) among PPIs that share their binding interface in a mutually exclusive manner with 0, 1 to 4, or 5 or more PPIs in the two human structural interactomes, Y2H-SI and Lit-SI. Error bars represent 95% confidence intervals.

From our edgotype predictions in Table 1, we calculated the probabilities for effectively neutral mutations and mildly deleterious mutations to disrupt PPIs belonging to either one of the three aforementioned groups in Y2H-SI and Lit-SI (Fig 5B and Table 2). Here, we also found a low enrichment of PPI disruptions by neutral mutations compared to mildly deleterious mutations among all three groups of PPIs (Table 2). Next, we integrated these probabilities into our Bayesian framework as before and calculated dispensable content among each group of PPIs. As a result, we estimated that <~20% of PPIs in each group are completely dispensable in both interactomes Y2H-SI and Lit-SI (Fig 5B and Table 2). These results reveal that dispensable content does not vary significantly with the number of mutually exclusive PPIs sharing the same binding interface.

Discussion

In a previous study, we estimated that <~20% of PPIs in the overall human interactome are completely dispensable, that is, effectively neutral upon disruption. While this estimate represents a grand average over the entire human interactome, it remains unknown how dispensable content varies across different subsets of the interactome involved in different biological processes and pathways, and across diverse groups of PPIs that exhibit different binding patterns across time and space. In this study, we took the first step towards addressing this question, by dividing the human interactome into two major groups of PPIs, transient and permanent, and estimating dispensable content among each group using a computational approach that we had developed and validated in previous studies. Overall, we estimate that <~20% of transient PPIs in human are completely dispensable. This fraction is similar to the fraction of dispensable PPIs calculated among permanent PPIs. Our results suggest that, similar to permanent PPIs, most transient PPIs in human are important to cellular function and are subject to similarly strong selective pressures in the human interactome.

Our estimates of dispensable content among transient PPIs and permanent PPIs were derived from predicted mutation edgotypes in two human structural interactomes, Y2H-SI which was derived from the HuRI dataset consisting of PPIs recently mapped by systematic Y2H screens [68], and Lit-SI which was derived from the literature-curated dataset of PPIs reported by at least two independent experiments in the IntAct database [71]. Our estimates of dispensable content for both transient and permanent PPIs calculated in both interactomes are broadly consistent with one another (<~20%). In addition, we also estimated the dispensable content among all PPIs together in the human interactome, using predicted mutation edgotypes in Y2H-SI and Lit-SI as well as mutation edgotypes obtained from experiments of Sahni et al. 2015. These estimates are also broadly consistent with one another (<~20%). Notably, our estimates of dispensable content derived in this study from the HuRI dataset and the IntAct literature-curated dataset are consistent with our previous estimates in [20] which were derived from much smaller datasets, the HI-II-14 dataset mapped by systematic Y2H screens [72] and an earlier version of literature-curated PPIs from the IntAct database.

Our study provides a comprehensive list of transient and permanent PPIs in human characterized using diverse structural and biophysical properties. These properties include, among others, the temporal and spatial co-expression of interaction partners, a property that has not been explored enough in recent literature especially on large-scale PPI datasets such as the HuRI dataset. While discrete properties such as the number of mutually exclusive PPIs sharing the same binding interface can be strong indicators of the transient or permanent nature of interaction, other properties such as binding affinity and the spatial and temporal co-expression of interaction partners may vary for some PPIs over a continuum of values overlapping between transient and permanent PPIs. For example, while transient PPIs tend to have weak binding affinities, it may be that some of them have stronger binding affinities closer to those of permanent PPIs. At the same time, while transient PPIs tend to have low co-expression levels and unbalanced stoichiometries between interaction partners, some of them may have higher co-expression levels and more balanced stoichiometries closer to those of permanent PPIs. Hence, there is no perfect borderline that separates transient PPIs from permanent PPIs based on such properties. Our study addresses this limitation by considering different structural, biophysical and spatiotemporal properties for classifying transient and permanent PPIs. These properties produce different sets of PPI classifications that are diverse enough to capture the aforementioned variabilities in PPI properties, but also with significant overlap (S5 Data). On average, a PPI is classified as transient by ~4 out of 8 properties in both Y2H-SI and Lit-SI, with 36% of PPIs in Y2H-SI and 40% of PPIs in Lit-SI classified as transient by 5 or more properties (Fig A in S1 Text). This diversity in PPI classifications results in a noticeable change across different PPI properties in the proportions P(T|N), P(T|M), P(P|N) and P(P|M) of neutral (N) and mildly deleterious (M) mutations that edgetically disrupt transient (T) and permanent (P) PPIs (Table 2). Nonetheless, the two ratios of proportions P(T|N)/P(T|M) and P(P|N)/P(P|M) are less affected by such changes (Table 2), resulting in estimates of dispensable PPI content that are broadly consistent across all PPI properties (<~20%). These results highlight the importance of considering different biophysical measurements in our study for classifying transient and permanent PPIs.

The high quality of our estimates of dispensable content among both transient PPIs and permanent PPIs depends on the quality of our predictions of transient and permanent interactions. Thus, we validated the performance of our computational approach for predicting transient and permanent PPIs using multiple experimental datasets. First, we benchmarked our FoldX-based predictions of PPI binding free energy (ΔG) against experimental ΔG values obtained from the Integrated Protein-Protein Interaction Benchmarks Database [61]. We selected PPIs with experimental ΔG < -12 kcal/mol (Kd < 10−9 M) to represent strong permanent interactions and those with experimental ΔG > -8 kcal/mol (Kd > 10−6 M) to represent weak transient interactions [62]. We then predicted ΔG values for these two groups of PPIs using FoldX. As a result, we obtained a Pearson correlation coefficient of 0.33 between predicted and experimental ΔG (p = 3.4 x 10−4), indicating that our FoldX predictions of PPI binding free energy are high quality. Next, we predicted PPIs to be transient or permanent using ΔG values calculated by FoldX, and compared our predictions to PPI classifications based on experimental ΔG values. For predicting transient PPIs, we obtained a balanced accuracy of 68%, a precision of 90%, a true positive rate (TPR) of 0.4, and a false positive rate (FPR) of 0.03. A TPR that is equal to FPR indicates that predictions are no better than random expectations. Our TPR is 13.3 times larger than our FPR (p = 7.2 x 10−7, two-sided Fisher’s exact test), further proving that our computational approach for predicting weak transient PPIs and strong permanent PPIs using FoldX-based ΔG calculations is very high-quality.

In addition to classifying PPIs based on strength of interaction, our study also classifies PPIs that are transient or permanent in time using three other properties: 1) low temporal co-expression for transient interaction partners versus high temporal co-expression for permanent interaction partners, 2) unbalanced stoichiometry for transient interactions versus balanced stoichiometry for permanent interactions, and 3) mutually exclusive binding for transient interactions versus simultaneously possible binding for permanent interactions. Thus, we validated our predictions of transient and permanent PPIs using these three properties on a manually-curated dataset of transient and permanent complexes in human derived from two independent studies by La et al. [62] and Mintseris and Weng [63]. For predicting transient PPIs based on temporal co-expression levels, we obtained a balanced accuracy of 70%, a precision of 99%, a TPR of 0.51, and a FPR of 0.1 (Table A in S1 Text). Our TPR in this case is 5.1 times larger than our FPR (p = 0.019, two-sided Fisher’s exact test), indicating that our predictions of temporally transient PPIs are very high quality and much better than random expectations. For predicting transient PPIs based on stoichiometry, we obtained a balanced accuracy of 56%, a precision of 97% and a TPR to FPR ratio of 1.4, albeit with an insignificant p-value (Table A in S1 Text). Finally, by predicting mutually exclusive PPIs to be transient and simultaneously possible PPIs to be permanent, we obtained a balanced accuracy of 78%, a precision of 98%, a TPR of 0.95, and a FPR of 0.4 (Table A in S1 Text). A TPR to FPR ratio of 2.4 (p = 1.1 x 10−5, two-sided Fisher’s exact test) further proves that our computational approach for predicting temporally transient PPIs and temporally permanent PPIs is high-quality. Notably, a large part of PPI classifications in the benchmark dataset of La et al. were derived from experimental ΔG values using rigid cut-offs and may contain some errors. Therefore, the quality of our computational predictions may be even better than what is observed by validation on this dataset.

Unlike the case for PPIs that are transient or permanent in time, experimental benchmark datasets for PPIs that are transient or permanent in space are not available. This is because while transience in time can be accurately detected through protein 3D structure analysis and other single-cell data analysis, detecting transience in space across multiple body tissues and in different cell types is more challenging and time-consuming. Nonetheless, a previous computational study by Bossi and Lehner has also attempted to predict spatially transient and spatially permanent PPIs based on gene co-expression levels in 79 human body tissues [67]. Unlike our study which classifies PPIs using gene expression data from the Illumina Body Map 2.0 project and the Fantom5 project, the study of Bossi and Lehner classified PPIs using gene expression data from the GNF Atlas project [80]. While such dataset may not be accurate enough to be considered a gold standard for benchmarking our predictions of transient and permanent PPIs, it provides an independent set of PPI classifications that can be used to validate our estimates of dispensable content among spatially transient and spatially permanent PPIs. Thus, we repeated our calculations of dispensable content, this time labelling spatially transient and spatially permanent PPIs using the dataset of Bossi and Lehner. We considered a PPI to be permanent in space if it was predicted by Bossi and Lehner to exist in at least 90% of the tissues, otherwise we considered the PPI to be transient in space. In Lit-SI, we estimated that ~6% of spatially transient PPIs are completely dispensable with a 95% confidence interval of ~3–11%, and that ~8% of spatially permanent PPIs are completely dispensable with a 95% confidence interval of ~3–19%. These estimates remain below 20% in agreement with our previous estimates. A similar calculation of dispensable content in the recently mapped interactome Y2H-SI was not possible due to lack of PPI classifications in the dataset of Bossi and Lehner, which only includes PPIs that were published in the literature at the time of their study.

Our study uses gene tissue expression data from the Illumina Body Map and Fantom5 projects to classify PPIs as spatially transient or spatially permanent. This expression data was measured in normal human body tissues. Our study also uses gene time-course expression data from the GEO database to classify PPIs as temporally transient or temporally permanent. This expression data was measured in different cell types under varying conditions. While it is very difficult to obtain detailed information about the health condition of subjects participating in these projects, it is possible that some gene expression levels may vary for individuals with certain diseases and in certain clinical settings, which may possibly introduce some errors into our classifications of transient and permanent PPIs. It is also possible that expression levels of some genes may be affected by mutations carried by the same gene. Our study assumes that gene expression samples were obtained from healthy individuals, which is true for the Illumina Body Map dataset and the Fantom5 dataset, but may not always be true for GEO data. Our study also assumes that the expression level of a gene is not affected by mutations in the gene itself. We address these limitations by considering other biophysical and structural properties of PPIs that are independent from gene expression levels, such as the strength of interaction and the number of mutually exclusive PPIs sharing the same binding interface. The consistency of our estimates of dispensable content using different PPI properties proves that our computational framework is robust to such possible sources of error. Furthermore, the high quality of our PPI classifications and estimates of dispensable PPI content as demonstrated by validations against multiple independent experimental and computational datasets of transient and permanent PPIs further proves the robustness of our study to such possible errors in PPI classifications. While mutation profiles associated with the gene expression samples that were used in this study are not available, sample information provided in our supplementary files may be used in the future for further investigation of mutation impact on gene expression.

Our structure-based edgotype prediction approach predicts that a mutation at the PPI binding interface edgetically disrupts the PPI if and only if it causes a change in binding free energy ΔΔG > 0.5 kcal/mol. This ΔΔG cut-off has been used and proven to provide high-quality predictions of PPI disruption in previous structural biology studies [20,21,81,82]. In addition, our Bayesian framework for estimating dispensable content has been shown to be robust to different choices of ΔΔG cut-off close to 0.5 kcal/mol, particularly 0.3 and 0.7 kcal/mol [21]. Nonetheless, it remains possible that some strong interactions require a change in binding energy significantly larger than our cut-off of 0.5 kcal/mol to be disrupted. In such cases, a mutation that causes a change in binding energy that is only slightly larger than 0.5 kcal/mol may be falsely predicted to disrupt the PPI by our computational approach. It is worth noting here that common mutations tend to have smaller ΔΔG values compared to disease mutations, with an average of 0.33 and 0.28 kcal/mol for common mutations in Y2H-SI and Lit-SI, respectively, compared to 1.1 and 0.9 kcal/mol for disease mutations, respectively (Fig B in S1 Text). Therefore, using a higher ΔΔG cut-off for predicting edgetic mutations is more likely to reduce the proportion of neutral mutations that are edgetic by a larger fraction compared to deleterious mutations, resulting in estimates of dispensable PPI content that are even lower than our current estimates. Indeed, we repeated our edgotype predictions and re-calculated dispensable content among both weak and strong PPIs using significantly higher ΔΔG cut-offs for predicting edgetic mutations: 1, 2 and 3 kcal/mol, and our estimates of dispensable content among both weak PPIs and strong PPIs remain below ~20% (Table B in S1 Text).

In our study, we used the FoldX method to calculate the change in PPI binding free energy upon mutation. Other computational methods are also available [83]. While FoldX uses only physics-based calculations to predict ΔΔG, other methods often make use of protein sequence and evolutionary information [83], which may introduce biases into our edgotype predictions for deleterious and neutral mutations. Furthermore, very few methods offer the option of predicting ΔΔG for thousands of mutations simultaneously in reasonable time like FoldX. Nonetheless, our previous studies have shown that our Bayesian framework for estimating dispensable PPI content and for estimating the overall fitness effect for different mutation edgotypes is robust to different choices of methods for predicting ΔΔG upon mutation [20,21], including the FoldX method [75], BindProfX [84], mCSM-PPI2 [85] and DynaMut2 [86]. At the same time, FoldX has been shown to provide high-quality predictions of binding ΔΔG in previous studies, with Pearson correlation coefficients ranging from 0.4 to 0.5 when benchmarked against comprehensive datasets of experimentally-determined ΔΔG values [83]. FoldX particularly outperforms other methods in identifying disease mutations [87]. An independent experiment performed by our recent study [20] reported Pearson correlation coefficients of 0.5 and 0.42 for ΔΔG values predicted by FoldX on co-crystal structures and homology models, respectively, when benchmarked against experimental data in the SKEMPI database [88]. In another study [21], we validated our FoldX-based edgotype prediction method on the experimental data of Sahni et al. [4] using a ΔΔG cut-off of 0.5 kcal/mol for predicting edgetic PPI disruption by mutation at the binding interface. Out of 23 mutations that were found to be edgetic in experiments, 7 were correctly predicted by our method to be edgetic, giving a true positive rate (TPR) of 0.3. On the other hand, out of 57 mutations that were found to be non-edgetic by experiments, only 2 were incorrectly predicted by our method to be edgetic, giving a false positive rate (FPR) of 0.04. A TPR that is equal to FPR indicates that predictions are no better than random expectations. Our TPR is 7.5 times larger than our FPR (p = 0.002, two-sided Fisher’s exact test), confirming again that our FoldX-based method for predicting edgetic PPI disruptions is very high-quality.

To further validate the high quality of our predicted mutation edgotypes and the resulting estimates of dispensable content, we estimated dispensable content for both transient and permanent PPIs this time using mutation edgotypes obtained from experiments of Sahni et al.. We first classified PPIs in the experimental dataset as either transient or permanent, in both time and space, as well as balanced or unbalanced in stoichiometry over both time and space, following the same procedures we used to classify PPIs in Y2H-SI and Lit-SI. It is worth noting here the very small size of the experimental dataset which consists of only 47 common mutations and 197 disease mutations, with only 2 common mutations and 62 disease mutations that are edgetic. Next, we calculated the fractions of mutations that are edgetic among transient PPIs (transient in time, transient in space, and unbalanced in stoichiometry) and the fraction of mutations that are edgetic among permanent PPIs (permanent in time, permanent in space, and balanced in stoichiometry), using edgotype data from experiments. Similar to our calculations in Y2H-SI and Lit-SI, we found that transient and permanent PPIs are both less likely to be disrupted by neutral mutations than by deleterious mutations (Tables C and D in S1 Text). We then estimated dispensable content among both transient PPIs and permanent PPIs using these edgotype results derived from experiments. Overall, our estimates are all below ~20%, consistent with our previous estimates obtained from predictions in Y2H-SI and Lit-SI, albeit with larger confidence intervals due to small sample size. These results derived from experimental mutation edgotypes further prove the high quality of our predicted mutation edgotypes and dispensable content estimates obtained from these predictions. A similar calculation of dispensable content among weak PPIs and strong PPIs and among mutually exclusive PPIs and simultaneously possible PPIs was not possible due to lack of structural data for the vast majority of PPIs that are disrupted by mutations in experiments.

Our calculations make a clear distinction between edgetic mutations and quasi-null mutations. While edgetic mutations disrupt specific PPIs by disrupting only the binding interface, quasi-null mutations disrupt all PPIs by disrupting overall protein stability thus creating other complex cellular and phenotypic changes that cannot be explained by simple PPI disruption. This distinction is not as simple in the experimental study of Sahni et al. due to lack of structural information. There, a mutation is considered to be edgetic if it disrupts at least one PPI but not all PPIs associated with a protein, and considered to be quasi-null if it disrupts all PPIs. This definition is not completely accurate since some edgetic mutations may disrupt all PPIs by disrupting the binding interface while maintaining overall protein stability, and will be misclassified as quasi-null. However, calculations in our previous study show that treating quasi-null mutations from experiments as if they were edgetic has a negligible impact on our estimate of dispensable content in the overall human interactome [20], indicating that our estimate of dispensable content derived from experiments is robust to such possible errors. At the same time, our calculations assume that each edgetic mutation disrupts one PPI, which is true for most edgetic mutations in Y2H-SI (50% of common mutations, and 58% of disease mutations) and in Lit-SI (82% of common mutations, and 66% of disease mutations). Nonetheless, to check whether our estimates of dispensable content are robust to the existence of edgetic mutations that disrupt more than one PPI, we repeated our calculations of dispensable content among both transient PPIs and permanent PPIs, this time replacing the fraction of mutations that are edgetic among common mutations and among disease mutations with the fraction of mutations that are mono-edgetic, i.e., those that disrupt only one PPI. Our results show that dispensable content among both transient and permanent PPIs remains below ~20% (Tables E and F in S1 Text), albeit with larger confidence intervals in some cases due to smaller sample size for mono-edgetic mutations (Table G in S1 Text).

Our estimates of dispensable PPI content are also robust to the presence of experimental false positives (“erroneous PPIs”) in PPI datasets [55,89]. These false positives mostly include physical interactions that are detected in vitro but do not occur in vivo, indirect interactions between proteins within the same complex that do not interact directly, as well as other stochastic artifacts that cannot be reproduced by independent experiments. Our structure-based approach includes several measures to minimize such false positive errors. First, we started with PPIs obtained from experiments rather than predictions. Second, the HuRI dataset was subjected to multiple Y2H screens and other quality control measures, and is similar in quality to a gold-standard dataset of literature-derived PPIs [68]. In addition, our IntAct-derived dataset includes only high-quality PPIs reported by at least two independent experiments in the literature. Furthermore, our structural interactomes include only PPIs for which we were able to construct homology models using experimentally determined 3D structural templates in PDB. Thus, our homology modelling approach enriches for true physical interactions and minimizes the occurrence of false positives.

Despite these quality control measures, it remains a possibility that some false positives may exist in our structural interactomes. In the presence of such errors, our estimates of dispensable content among both transient PPIs and permanent PPIs represent upper bounds. This is because erroneous PPIs have no biological power to discriminate between neutral and deleterious mutations. Thus, in the false positive portion of the PPI dataset, the probability for an edgetic mutation that disrupts a PPI to be effectively neutral is independent of the mutation edgotype and is similar to the prior probability for any missense mutation to be effectively neutral, which is ~27%. Our estimates of dispensable content among both transient PPIs and permanent PPIs are defined as the probability for an edgetic mutation that disrupts such PPIs to be effectively neutral. These estimates represent the average calculated over the mixed dataset of true PPIs and erroneous PPIs, and are both lower than ~20%. Therefore, the fraction of dispensable PPIs calculated in the error-free portion of the dataset will be even lower than our average estimates.

The prior probabilities P(N), P(M) and P(S) were obtained from a genome-wide population genetics study that is completely independent from our edgotype predictions [76]. These prior probabilities are high-quality, as they were subjected to multiple quality-control measures. Nonetheless, it remains a possibility that the error margins associated with these probabilities are not negligible. Our conclusions are also robust to such possible errors. From Eq 1 in the Methods section, it is clear that the fraction of type-T PPIs that are effectively neutral (N) upon edgetic disruption P(N|T) depends only on the two ratios P(M)/P(N) and P(T|M)/P(T|N) as follows:

1P(N|T)=1+P(M)P(N)P(T|M)P(T|N)

Our upper limit of ~20% based on the 95% confidence intervals for dispensable content among both transient PPIs and permanent PPIs corresponds to the ratios P(M)/P(N) = ~2 and P(T|M)/P(T|N) = ~2. If instead of the literature-derived priors, we assume uninformative priors where P(M)/P(N) = 1, our upper limit on dispensable content will only increase from ~20% to ~33%, and we still conclude that most transient PPIs in human are indispensable. Finally, since we used the same prior probabilities to estimate the dispensable content for both transient and permanent PPIs, different choices of prior probabilities will not change our conclusion that the dispensable content for transient interactions is similar to that for permanent interactions. Our conclusion is driven primarily by the observation that while disease mutations are significantly more likely to edgetically disrupt PPIs than common mutations, the propensity for common mutations to disrupt PPIs relative to disease mutations is roughly the same among both transient PPIs and permanent PPIs. These propensities are independent of the prior probabilities used in our Bayesian framework for calculating dispensable PPI content.

The ideal way of calculating dispensable content among transient or permanent PPIs is to first perform large-scale experiments to determine whether each PPI in the human interactome is transient or permanent. Such experiments involve many challenges such as measuring the binding affinity and/or the duration of each interaction, determining whether each interaction exists or does not exist in each body tissue, and also monitoring the stoichiometry for each pair of interacting proteins over the course of interaction. The second step would be to systematically disrupt PPIs one at a time and measure the fitness change of the cell in response to each disruption. In the absence of such challenging experiments, our computational approach offers the next best solution by first classifying transient and permanent interactions using structure-based calculations as well as protein abundance measurements, predicting PPI disruptions by mutations using structure-based calculations, and finally examining the phenotypic consequences of mutations disrupting as few as one PPI at a time while maintaining all other aspects of cell biology such as protein stability, protein expression, and other molecular interactions. All these steps in our computational framework have proven to be very high-quality when benchmarked against multiple experimental datasets and therefore greatly complement experimental efforts.

In summary, we estimate that <~20% of transient PPIs in the human structural interactome are completely dispensable, similar to permanent PPIs, suggesting that most transient PPIs in the human structural interactome carry out important cellular functions and are at least mildly deleterious upon disruption. This estimate represents an average over all transient PPIs in the structural interactome and is likely to vary significantly across the entire human interactome. For example, dispensable content may be higher among transient PPIs mediated specifically by motif-domain interactions in intrinsically disordered regions [33,34]. Selective pressures may also be lower among transient PPIs mediated by protein domains from recently much expanded families compared to PPIs mediated by more conserved domains [90]. While our study is only concerned about estimating the average fraction of dispensable PPIs among all transient PPIs in the human structural interactome, it remains to be seen whether the dispensable content varies significantly for these different groups of transient PPIs in the entire human interactome. At the same time, PPIs that are completely dispensable across closely related species are expected to be less likely to be conserved across these species. That being said, PPIs that are completely dispensable in human may not be dispensable in other closely related species such as chimp and mouse, and as such they may or may not be conserved among closely related species. With currently incomplete PPI experimental datasets (with high false negative rates), it is hard to determine whether a specific PPI that is dispensable in human is conserved or not in another species. Nonetheless, recent genome-wide screens suggest that ~50% of PPIs in human are lost in budding yeast [9]. Our current study suggests that at most ~20% of PPIs are completely dispensable in human (for both transient and permanent PPIs). Taken together, these results suggest that at least ~30% of PPIs are rewired between human and yeast not because they are unimportant in both species, but rather due to other factors such as lineage-specific adaption. While it has been shown that transient PPIs are more likely to rewire during evolution than permanent PPIs [12,35,5052], these rewiring events may be driven by many complex evolutionary forces, including both non-adaptive (e.g., genetic drift on dispensable PPIs) and adaptive (e.g., lineage-specific adaptation) processes. In addition, while the removal of a single dispensable PPI has no impact on organismal fitness, in some cases it may decrease the organism’s robustness against further disruptions of the interactome, for example when an important biological function is carried out by multiple redundant PPIs. Thus, the relationship between dispensability and evolutionary rate is a complex and significant research topic in and of itself, previously only investigated for proteins [9193], but never for PPIs. While our current study is focused on PPI dispensability in human, the relationship between dispensability, its underlying molecular mechanisms and evolutionary rate for PPIs should be further investigated in future work.

Methods

Building the human structural interactome

Three-dimensional (3D) protein complex structures at atomic resolution were obtained from PDB [60]. For structures containing more than one model, the first model was selected. Gene Ensembl IDs in the HuRI reference interactome were mapped to protein UniProt IDs and corresponding amino acid sequences using the ID mapping table provided by UniProt [94]. For proteins in the IntAct reference interactome, UniProt IDs provided by the IntAct database were used to obtain corresponding amino acid sequences. Next, we used BLAST [95] to perform sequence alignment of all protein sequences against all PDB chain sequences found in PDB’s SEQRES records, with an E-value cut-off of 10−5. For each pair of protein sequence and PDB chain, the alignment with the smallest E-value was retained, and the remaining alignments were discarded. A PPI was annotated with a pair of chains found in the same PDB structure if: (i) the two chains had a binding interface, (ii) one of the proteins in the PPI has a sequence alignment with one of the chains in the chain pair with ≥50% of interface residues mapped onto the protein; and (iii) the other protein in the PPI has a sequence alignment with the other chain in the chain pair with ≥50% of interface residues mapped onto the protein. PPIs having no PDB chain-pair annotations were discarded. The 3D structure corresponding to the annotated chain-pair of each PPI was selected as a template for generating the PPI structural model. We then used BLAST again to generate the sequence alignment for each PPI against residues with 3D coordinates available in the template file. These alignments were then used to construct PPI structural models with the MODELLER library (version 9.23) [96]. Interface residues for each PPI were identified by calculating the pair-wise Euclidean distance between residues across the two chains in the structural model. The distance between two residues was calculated as the minimum distance between all atoms of the first residue and all atoms of the second residue. Residues in each chain that are within a distance of 5Å from any residue in the other chain were labelled as interface residues.

Processing disease mutations

Germline mutations in human with associated phenotypic consequences were retrieved in February 2020 from the ClinVar database (genome assembly GRCh38) [73]. We selected missense mutations that are strictly labelled as pathogenic only, with supporting evidence (i.e., with at least one star), and with no conflicting phenotypic interpretations.

Processing common mutations

Single Nucleotide Polymorphisms (SNPs) in human were retrieved in February 2020 from the Single Nucleotide Polymorphism Database (dbSNP) (build 150 GRCh38p7) [74]. First, we selected only missense mutations that are labelled as validated and not withdrawn, and are assigned a location on the RefSeq transcript of a protein. Next, we discarded all mutations labelled with disease assertions (e.g., pathogenic, likely pathogenic, drug-response, uncertain significance or other). Finally, we selected mutations that have minor allele frequencies ≥1%, as common mutations with high frequencies are unlikely to be associated with any disease.

Mapping mutations onto the human structural interactome

We searched the protein RefSeq transcript associated with each mutation for the mutation flanking sequence, defined as either the first 10 amino acid residues or all amino acid residues, whichever one is shorter, on both sides of the mutation. Then we searched the protein’s sequence designated by UniProt for the mutation flanking sequence obtained from the RefSeq transcript. If the flanking sequence was found on the protein UniProt sequence at the same position reported on the RefSeq transcript, the mutation was retained for further analysis, otherwise the mutation was discarded. For multiple mutations mapping onto the same position, only one mutation was retained for further analysis. Common mutations overlapping in position with disease mutations were also discarded. Finally, mutations located at PPI binding interfaces were identified using residue position mappings between protein UniProt sequences and PPI structural models.

Calculating change in PPI binding free energy upon mutation

PPI structural models were first repaired using the RepairPDB command in FoldX. Change in PPI binding free energy (ΔΔG) was then calculated for each interfacial mutation on the repaired structural model using the BuildModel command in FoldX with default parameters (temperature = 298, pH = 7.0, ionStrength = 0.05, water = -IGNORE, vdwDesign = 2).

Calculating PPI binding free energy

PPI structural templates were first repaired using the RepairPDB command in FoldX. Binding free energy (ΔG) was then calculated on repaired PPI structural templates using the AnalyseComplex command in FoldX with default parameters (temperature = 298, pH = 7.0, ionStrength = 0.05, water = -IGNORE, vdwDesign = 2).

Processing gene tissue expression profiles

Gene tissue expression data in human was retrieved from two databases: the Illumina Body Map 2.0 project with RNA-Seq data quantified in 16 normal human body tissues [78], and the Fantom5 project with CAGE (Cap Analysis of Gene Expression) peaks (tags per million) for gene promoters in 183 normal human body tissue samples [79]. For Illumina Body Map data, gene expression profiles were paired with proteins in the structural interactome by mapping gene names to protein UniProt IDs using UniProt’s ID mapping table. For Fantom5 data, promoter CAGE peaks were paired with proteins in the structural interactome by mapping gene HGNC IDs to protein UniProt IDs using UniProt’s ID mapping table. For genes with multiple CAGE peaks, the average over all peaks was considered. Tissue co-expression levels for pairs of proteins were then calculated using Pearson’s correlation coefficient of their gene tissue expression profiles. Only protein pairs whose expression levels are defined together in at least 5 tissues were considered.

Processing gene time-course expression profiles

Gene time-course expression data in human was retrieved from the Gene Expression Omnibus [77] by searching the database for curated datasets having the term ‘time course’ in their title or description. In total, we obtained 223 datasets for human. We then selected 63 datasets that have gene expression levels measured over at least 5 time points, with multiple samples averaged for each time point. Gene expression profiles in each experiment were paired with proteins in the structural interactome by mapping gene names to protein UniProt IDs using UniProt’s ID mapping table. Time-course co-expression for pairs of proteins in each experiment was then calculated using Pearson’s correlation coefficient of their gene expression profiles.

Calculating the fraction of completely dispensable PPIs

Each mutation either edgetically disrupts a PPI of type T or does not edgetically disrupt a PPI of type T. In addition, the fitness effect of a mutation can be either neutral, mildly deleterious, or strongly detrimental. From mutation edgotype data, we obtain the probability P(T|N) for neutral (N) mutations to edgetically disrupt a type-T PPI and the probability P(T|M) for mildly deleterious (M) mutations to edgetically disrupt a type-T PPI. Furthermore, we obtain from Kryukov et al. [76] the probabilities for new missense mutations to be effectively neutral (N), mildly deleterious (M), or strongly detrimental (S): P(N) = 27%, P(M) = 53%, P(S) = 20%. We then integrate these probabilities together to calculate the probability for a new missense mutation to edgetically disrupt a type-T PPI:

P(T)=P(T|N)P(N)+P(T|M)P(M)+P(T|S)P(S) (Eq 1)

where P(T|S) ≈ 0 assuming that strongly detrimental mutations are quasi-null rather than edgetic. Finally, we apply Bayes’ theorem P(A|B) = P(B|A)P(A)/P(B) to calculate the fraction of type-T PPIs that are completely dispensable, defined as the probability for a mutation that edgetically disrupts a type-T PPI to be effectively neutral (N):

P(N|T)=P(T|N)P(N)P(T) (Eq 2)

Below, we describe the procedure for calculating the 95% confidence interval for P(N|T).

By substituting P(T) = P(T|N)P(N) + P(T|M)P(M) from Eq 1 into Eq 2, it is easy to see that P(N|T) only depends on the ratio P(T|M)/P(T|N) in the following way:

1P(N|T)=1+P(T|M)P(T|N)P(M)P(N) (Eq 3)

where P(M)/P(N) is a constant. The 95% confidence interval for the ratio of two proportions P(T|M)/P(T|N) was calculated according to Bland [97], which was then used to calculate the 95% confidence interval for P(N|T) using Eq 3.

Supporting information

S1 Data. The human structural interactome.

PPIs in the human structural interactome annotated with interface residue positions on canonical protein sequences from UniProt. (A) Y2H-SI. (B) Lit-SI.

(XLSX)

S2 Data. Edgetic PPI disruptions and mutation edgotypes.

(A) Common mutations in Y2H-SI. (B) Disease mutations in Y2H-SI. (C) Common mutations in Lit-SI. (D) Disease mutations in Lit-SI.

(XLSX)

S3 Data. PPI change in binding free energy.

PPI change in binding free energy (ΔΔG) upon mutation calculated on PPI structural models. (A) Common mutations in Y2H-SI. (B) Disease mutations in Y2H-SI. (C) Common mutations in Lit-SI. (D) Disease mutations in Lit-SI.

(XLSX)

S4 Data. PPI binding free energy.

PPI binding free energy (ΔG) calculated on PPI structural templates from PDB.. (A) Y2H-SI. (B) Lit-SI.

(XLSX)

S5 Data. PPI classifications.

(A) Y2H-SI. (B) Lit-SI.

(XLSX)

S6 Data. Gene expression sample information.

(A) Sample counts and time points for all 63 datasets from GEO. (B) Names of the 16 tissues in the Illumina Body Map 2.0 dataset. (C) Names of the 183 tissue samples in the Fantom5 dataset.

(XLSX)

S7 Data. Co-expression of interaction partners.

(A) Time-course co-expression in 63 GEO datasets for PPIs in Y2H-SI. (B) Time-course co-expression in 63 GEO datasets for PPIs in Lit-SI. (C) Tissue co-expression based on Illumina Body Map and Fantom5 data for PPIs in Y2H-SI. (D) Tissue co-expression based on Illumina Body Map and Fantom5 data for PPIs in Lit-SI.

(XLSX)

S8 Data. Time-course abundance of interaction partners.

Difference in the log10 of time-course expression levels for interaction partners in the human structural interactome. (A) Expression difference at each time point in 63 GEO datasets for PPIs in Y2H-SI. (B) Expression difference at each time point in 63 GEO datasets for PPIs in Lit-SI.

(XLSX)

S9 Data. Tissue-based abundance of interaction partners.

Difference in the log10 of tissue-based expression levels for interaction partners in the human structural interactome. (A) Expression difference among 16 tissues from Illumina Body Map for PPIs in Y2H-SI. (B) Expression difference among 16 tissues from Illumina Body Map for PPIs in Lit-SI. (C) Expression difference among 183 tissue samples from Fantom5 for PPIs in Y2H-SI. (D) Expression difference among 183 tissues samples from Fantom5 for PPIs in Lit-SI.

(XLSX)

S10 Data. Mutually exclusive and simultaneously possible PPIs.

(A) Y2H-SI. (B) Lit-SI.

(XLSX)

S1 Text

Fig A in S1 Text. Distribution of PPI transient classifications across multiple properties. Distribution of the number of times a PPI was classified as transient based on 8 different structural and biophysical measurements: PPI strength, transience in time (based on gene expression levels), transience in space (based on gene expression and promotor activity levels), stoichiometry in time (based on gene expression levels), stoichiometry in space (based on gene expression and promotor activity levels), and number of mutually exclusive PPIs.

Fig B in S1 Text. Change in PPI binding free energy upon mutation. Change in PPI binding free energy (ΔΔG) distribution for all disease and common non-disease interfacial mutations in both structural interactomes Y2H-SI and Lit-SI. ΔΔG values were calculated using FoldX.

Table A in S1 Text. Performance of predictions of temporally transient and permanent PPIs. Performance measures for predicting temporally transient PPIs and temporally permanent PPIs in human when benchmarked against experimental data combined from La et al. (2013) and Mintseris and Weng (2003).

Table B in S1 Text. Dispensable content derived from different binding ΔΔG cut-offs. Dispensable content among weak and strong PPIs calculated using different binding ΔΔG cut-offs for predicting edgetic disruptions of PPIs in the two human structural interactomes Y2H-SI and Lit-SI.

Table C in S1 Text. Edgetic mutation data derived from experiments. Number of common mutations and disease mutations in the experimental data of Sahni et al. 2015 that edgetically disrupt transient and permanent PPIs as defined by different biophysical and spatiotemporal properties. PPI disruptions by mutations were obtained from experiments of Sahni et al. 2015. PPI classifications were determined computationally.

Table D in S1 Text. Dispensable content among transient and permanent PPIs in experiments. Edgotype probabilities for neutral and mildly deleterious mutations in the experimental data of Sahni et al. 2015 calculated among transient and permanent PPIs directly from Table C, assuming that common mutations are effectively neutral (N) and that disease mutations are mildly deleterious (M) on average. The resulting dispensable contents P(N|T) and P(N|P) among both transient (T) and permanent (P) PPIs were calculated using Bayes’ theorem. Columns represent the following, P(T|N): probability (%) for neutral mutations (N) to edgetically disrupt transient PPIs (T), P(T|M): probability (%) for mildly deleterious mutations (M) to edgetically disrupt transient PPIs (T), P(N|T): dispensable content among transient PPIs defined as the probability (%) for transient PPIs to be effectively neutral upon disruption, P(P|N): probability (%) for neutral mutations (N) to edgetically disrupt permanent PPIs (P), P(P|M): probability (%) for mildly deleterious mutations (M) to edgetically disrupt permanent PPIs (P), P(N|P): dispensable content among permanent PPIs defined as the probability (%) for permanent PPIs to be effectively neutral upon disruption. CI: 95% confidence interval (%) for dispensable contents P(N|T) and P(N|P). PPI disruptions by mutations were obtained from experiments of Sahni et al. 2015. PPI classifications were determined computationally.

Table E in S1 Text. Mono-edgetic mutation data obtained from predictions. Number of common mutations and disease mutations that edgetically disrupt a single transient PPI or permanent PPI defined by different structural, biophysical and spatiotemporal properties in the two human structural interactomes Y2H-SI and Lit-SI.

Table F in S1 Text. Dispensable content among transient and permanent PPIs based on mono-edgetic mutations. Edgotype probabilities for neutral and mildly deleterious mutations calculated directly from edgotype numbers in Table E, assuming that common mutations are effectively neutral (N) and that disease mutations are mildly deleterious (M) on average. The resulting dispensable contents P(N|T) and P(N|P) among both transient (T) and permanent (P) PPIs were calculated using Bayes’ theorem. Columns represent the following, SI: structural interactome, P(T|N): probability (%) for neutral mutations (N) to edgetically disrupt a single transient PPI (T), P(T|M): probability (%) for mildly deleterious mutations (M) to edgetically disrupt a single transient PPI (T), P(N|T): dispensable content among transient PPIs defined as the probability (%) for transient PPIs to be effectively neutral upon disruption, P(P|N): probability (%) for neutral mutations (N) to edgetically disrupt a single permanent PPI (P), P(P|M): probability (%) for mildly deleterious mutations (M) to edgetically disrupt a single permanent PPI (P), P(N|P): dispensable content among permanent PPIs defined as the probability (%) for permanent PPIs to be effectively neutral upon disruption.

Table G in S1 Text. Confidence intervals for dispensable content based on mono-edgetic mutations. 95% confidence intervals for estimates of dispensable content P(N|T) and P(N|P) in Table F based on mono-edgetic mutations.

(PDF)

Data Availability

The source data underlying all figures are included in this article and its supplementary data files. Code that was used to build the human structural interactome is available at the following GitHub repository: https://github.com/MohamedGhadie/build_structural_interactome. Code that was used to map mutations onto the human structural interactome and calculate dispensable content among transient PPIs and permanent PPIs is available at the following GitHub repository: https://github.com/MohamedGhadie/dispensable_transient_ppis.

Funding Statement

This work was supported by Natural Sciences and Engineering Research Council of Canada grants RGPIN-2019-05952 and RGPAS-2019-00012, Canada Foundation for Innovation grant JELF-33732, and Canada Research Chairs program to Y.X.. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Yang X, Coulombe-Huntington J, Kang S, Sheynkman Gloria M, Hao T, Richardson A, et al. Widespread Expansion of Protein Interaction Capabilities by Alternative Splicing. Cell. 2016;164(4):805–17. doi: 10.1016/j.cell.2016.01.029 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Cowen L, Ideker T, Raphael BJ, Sharan R. Network propagation: a universal amplifier of genetic associations. Nat Rev Genet. 2017;18(9):551–62. doi: 10.1038/nrg.2017.38 [DOI] [PubMed] [Google Scholar]
  • 3.Menche J, Sharma A, Kitsak M, Ghiassian SD, Vidal M, Loscalzo J, et al. Uncovering disease-disease relationships through the incomplete interactome. Science. 2015;347(6224):1257601. doi: 10.1126/science.1257601 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Sahni N, Yi S, Taipale M, Fuxman Bass Juan I, Coulombe-Huntington J, Yang F, et al. Widespread Macromolecular Interaction Perturbations in Human Genetic Disorders. Cell. 2015;161(3):647–60. doi: 10.1016/j.cell.2015.04.013 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Caldera M, Buphamalai P, Müller F, Menche J. Interactome-based approaches to human disease. Curr Opin Syst Biol. 2017;3:88–94. 10.1016/j.coisb.2017.04.015. [DOI] [Google Scholar]
  • 6.Yi S, Lin S, Li Y, Zhao W, Mills GB, Sahni N. Functional variomics and network perturbation: connecting genotype to phenotype in cancer. Nat Rev Genet. 2017;18(7):395–410. doi: 10.1038/nrg.2017.8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Kar G, Gursoy A, Keskin O. Human Cancer Protein-Protein Interaction Network: A Structural Perspective. PLoS Comp Biol. 2009;5(12):e1000601. doi: 10.1371/journal.pcbi.1000601 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Das J, Vo TV, Wei X, Mellor JC, Tong V, Degatano AG, et al. Cross-Species Protein Interactome Mapping Reveals Species-Specific Wiring of Stress Response Pathways. Sci Signal. 2013;6(276):ra38. doi: 10.1126/scisignal.2003350 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Vo Tommy V, Das J, Meyer Michael J, Cordero Nicolas A, Akturk N, Wei X, et al. A Proteome-wide Fission Yeast Interactome Reveals Network Evolution Principles from Yeasts to Human. Cell. 2016;164(1):310–23. doi: 10.1016/j.cell.2015.11.037 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Zhong Q, Pevzner SJ, Hao T, Wang Y, Mosca R, Menche J, et al. An inter-species protein–protein interaction network across vast evolutionary distance. Mol Syst Biol. 2016;12(4):865. doi: 10.15252/msb.20156484 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Ghadie MA, Coulombe-Huntington J, Xia Y. Interactome evolution: insights from genome-wide analyses of protein–protein interactions. Curr Opin Struct Biol. 2018;50:42–8. doi: 10.1016/j.sbi.2017.10.012 [DOI] [PubMed] [Google Scholar]
  • 12.Kim PM, Lu LJ, Xia Y, Gerstein MB. Relating Three-Dimensional Structures to Protein Networks Provides Evolutionary Insights. Science. 2006;314(5807):1938. doi: 10.1126/science.1136174 [DOI] [PubMed] [Google Scholar]
  • 13.Franzosa EA, Xia Y. Structural principles within the human-virus protein-protein interaction network. Proc Natl Acad Sci. 2011;108(26):10538. doi: 10.1073/pnas.1101440108 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Wang X, Wei X, Thijssen B, Das J, Lipkin SM, Yu H. Three-dimensional reconstruction of protein networks provides insight into human genetic disease. Nat Biotechnol. 2012;30(2):159–64. doi: 10.1038/nbt.2106 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Garamszegi S, Franzosa EA, Xia Y. Signatures of Pleiotropy, Economy and Convergent Evolution in a Domain-Resolved Map of Human–Virus Protein–Protein Interaction Networks. PLoS Path. 2013;9(12):e1003778. doi: 10.1371/journal.ppat.1003778 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Mosca R, Céol A, Aloy P. Interactome3D: adding structural details to protein networks. Nat Methods. 2013;10(1):47–53. doi: 10.1038/nmeth.2289 [DOI] [PubMed] [Google Scholar]
  • 17.Ghadie MA, Lambourne L, Vidal M, Xia Y. Domain-based prediction of the human isoform interactome provides insights into the functional impact of alternative splicing. PLoS Comp Biol. 2017;13(8):e1005717. doi: 10.1371/journal.pcbi.1005717 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Ozdemir ES, Gursoy A, Keskin O. Analysis of single amino acid variations in singlet hot spots of protein–protein interfaces. Bioinformatics. 2018;34(17):i795–i801. doi: 10.1093/bioinformatics/bty569 [DOI] [PubMed] [Google Scholar]
  • 19.Ozdemir ES, Halakou F, Nussinov R, Gursoy A, Keskin O. Methods for Discovering and Targeting Druggable Protein-Protein Interfaces and Their Application to Repurposing. In: Vanhaelen Q, editor. Computational Methods for Drug Repurposing. New York, NY: Springer New York; 2019. p. 1–21. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Ghadie M, Xia Y. Estimating dispensable content in the human interactome. Nat Commun. 2019;10(1):3205. doi: 10.1038/s41467-019-11180-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Ghadie M, Xia Y. Mutation Edgotype Drives Fitness Effect in Human. Frontiers in Bioinformatics. 2021;1:690769. doi: 10.3389/fbinf.2021.690769 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Nooren IMA, Thornton JM. Diversity of protein–protein interactions. EMBO J. 2003;22(14):3486–92. doi: 10.1093/emboj/cdg359 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Acuner Ozbabacan SE, Engin HB, Gursoy A, Keskin O. Transient protein–protein interactions. Protein Eng Des Sel. 2011;24(9):635–48. doi: 10.1093/protein/gzr025 [DOI] [PubMed] [Google Scholar]
  • 24.Aloy P, Russell RB. Ten thousand interactions for the molecular biologist. Nat Biotechnol. 2004;22(10):1317–21. doi: 10.1038/nbt1018 [DOI] [PubMed] [Google Scholar]
  • 25.Jansen R, Greenbaum D, Gerstein M. Relating whole-genome expression data with protein-protein interactions. Genome Res. 2002;12(1):37–46. doi: 10.1101/gr.205602 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Han J-DJ, Bertin N, Hao T, Goldberg DS, Berriz GF, Zhang LV, et al. Evidence for dynamically organized modularity in the yeast protein–protein interaction network. Nature. 2004;430(6995):88–93. doi: 10.1038/nature02555 [DOI] [PubMed] [Google Scholar]
  • 27.Perkins JR, Diboun I, Dessailly BH, Lees JG, Orengo C. Transient Protein-Protein Interactions: Structural, Functional, and Network Properties. Structure. 2010;18(10):1233–43. doi: 10.1016/j.str.2010.08.007 [DOI] [PubMed] [Google Scholar]
  • 28.Greene CS, Krishnan A, Wong AK, Ricciotti E, Zelaya RA, Himmelstein DS, et al. Understanding multicellular function and disease with human tissue-specific networks. Nat Genet. 2015;47(6):569–76. doi: 10.1038/ng.3259 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Marsh JA, Rees HA, Ahnert SE, Teichmann SA. Structural and evolutionary versatility in protein complexes with uneven stoichiometry. Nat Commun. 2015;6(1):6394. doi: 10.1038/ncomms7394 [DOI] [PubMed] [Google Scholar]
  • 30.Vidal M, Cusick Michael E, Barabási A-L. Interactome Networks and Human Disease. Cell. 2011;144(6):986–98. doi: 10.1016/j.cell.2011.02.016 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Huttlin EL, Bruckner RJ, Paulo JA, Cannon JR, Ting L, Baltier K, et al. Architecture of the human interactome defines protein communities and disease networks. Nature. 2017;545(7655):505–9. doi: 10.1038/nature22366 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Leducq J-B, Charron G, Diss G, Gagnon-Arsenault I, Dubé AK, Landry CR. Evidence for the Robustness of Protein Complexes to Inter-Species Hybridization. PLoS Genet. 2012;8(12):e1003161. doi: 10.1371/journal.pgen.1003161 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Landry CR, Levy ED, Michnick SW. Weak functional constraints on phosphoproteomes. Trends Genet. 2009;25(5):193–7. doi: 10.1016/j.tig.2009.03.003 [DOI] [PubMed] [Google Scholar]
  • 34.Levy ED, Michnick SW, Landry CR. Protein abundance is key to distinguish promiscuous from functional phosphorylation based on evolutionary information. Philos Trans R Soc Lond B Biol Sci. 2012;367(1602):2594–606. doi: 10.1098/rstb.2012.0078 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Studer RA, Rodriguez-Mias RA, Haas KM, Hsu JI, Viéitez C, Solé C, et al. Evolution of protein phosphorylation across 18 fungal species. Science. 2016;354(6309):229. doi: 10.1126/science.aaf2144 [DOI] [PubMed] [Google Scholar]
  • 36.Blundell TL, Fernández-Recio J. Brief encounters bolster contacts. Nature. 2006;444(7117):279–80. doi: 10.1038/nature05306 [DOI] [PubMed] [Google Scholar]
  • 37.Tang C, Iwahara J, Clore GM. Visualization of transient encounter complexes in protein–protein association. Nature. 2006;444(7117):383–6. doi: 10.1038/nature05201 [DOI] [PubMed] [Google Scholar]
  • 38.Nyfeler B, Michnick SW, Hauri H-P. Capturing protein interactions in the secretory pathway of living cells. Proc Natl Acad Sci USA. 2005;102(18):6350. doi: 10.1073/pnas.0501976102 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Sungkaworn T, Jobin M-L, Burnecki K, Weron A, Lohse MJ, Calebiro D. Single-molecule imaging reveals receptor–G protein interactions at cell surface hot spots. Nature. 2017;550(7677):543–7. doi: 10.1038/nature24264 [DOI] [PubMed] [Google Scholar]
  • 40.Thomas GM, Huganir RL. MAPK cascade signalling and synaptic plasticity. Nat Rev Neurosci. 2004;5(3):173–83. doi: 10.1038/nrn1346 [DOI] [PubMed] [Google Scholar]
  • 41.Kholodenko BN. Cell-signalling dynamics in time and space. Nat Rev Mol Cell Biol. 2006;7(3):165–76. doi: 10.1038/nrm1838 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Liu Y, Shepherd EG, Nelin LD. MAPK phosphatases—regulating the immune response. Nat Rev Immunol. 2007;7(3):202–12. doi: 10.1038/nri2035 [DOI] [PubMed] [Google Scholar]
  • 43.Wu K, Stull F, Lee C, Bardwell JCA. Protein folding while chaperone bound is dependent on weak interactions. Nat Commun. 2019;10(1):4833. doi: 10.1038/s41467-019-12774-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Rosenzweig R, Nillegoda NB, Mayer MP, Bukau B. The Hsp70 chaperone network. Nat Rev Mol Cell Biol. 2019;20(11):665–80. doi: 10.1038/s41580-019-0133-3 [DOI] [PubMed] [Google Scholar]
  • 45.Moll UM, Wolff S, Speidel D, Deppert W. Transcription-independent pro-apoptotic functions of p53. Curr Opin Cell Biol. 2005;17(6):631–6. doi: 10.1016/j.ceb.2005.09.007 [DOI] [PubMed] [Google Scholar]
  • 46.Bieging KT, Mello SS, Attardi LD. Unravelling mechanisms of p53-mediated tumour suppression. Nat Rev Cancer. 2014;14(5):359–70. doi: 10.1038/nrc3711 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Vishwanath S, Sukhwal A, Sowdhamini R, Srinivasan N. Specificity and stability of transient protein–protein interactions. Curr Opin Struct Biol. 2017;44:77–86. doi: 10.1016/j.sbi.2016.12.010 [DOI] [PubMed] [Google Scholar]
  • 48.Cumberworth A, Lamour G, Babu MM, Gsponer J. Promiscuity as a functional trait: intrinsically disordered regions as central players of interactomes. Biochem J. 2013;454(3):361–9. doi: 10.1042/BJ20130545 [DOI] [PubMed] [Google Scholar]
  • 49.Tompa P, Davey Norman E, Gibson Toby J, Babu MM. A Million Peptide Motifs for the Molecular Biologist. Mol Cell. 2014;55(2):161–9. doi: 10.1016/j.molcel.2014.05.032 [DOI] [PubMed] [Google Scholar]
  • 50.Mintseris J, Weng Z. Structure, function, and evolution of transient and obligate protein–protein interactions. Proc Natl Acad Sci. 2005;102(31):10930. doi: 10.1073/pnas.0502667102 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Beltrao P, Serrano L. Specificity and Evolvability in Eukaryotic Protein Interaction Networks. PLoS Comp Biol. 2007;3(2):e25. doi: 10.1371/journal.pcbi.0030025 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Sun MGF, Sikora M, Costanzo M, Boone C, Kim PM. Network Evolution: Rewiring and Signatures of Conservation in Signaling. PLoS Comp Biol. 2012;8(3):e1002411. doi: 10.1371/journal.pcbi.1002411 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Schilder J, Ubbink M. Formation of transient protein complexes. Curr Opin Struct Biol. 2013;23(6):911–8. doi: 10.1016/j.sbi.2013.07.009 [DOI] [PubMed] [Google Scholar]
  • 54.Cafarelli TM, Desbuleux A, Wang Y, Choi SG, De Ridder D, Vidal M. Mapping, modeling, and characterization of protein–protein interactions on a proteomic scale. Curr Opin Struct Biol. 2017;44:201–10. doi: 10.1016/j.sbi.2017.05.003 [DOI] [PubMed] [Google Scholar]
  • 55.Wodak SJ, Vlasblom J, Turinsky AL, Pu S. Protein–protein interaction networks: the puzzling riches. Curr Opin Struct Biol. 2013;23(6):941–53. doi: 10.1016/j.sbi.2013.08.002 [DOI] [PubMed] [Google Scholar]
  • 56.Kumar M, Gouw M, Michael S, Sámano-Sánchez H, Pancsa R, Glavina J, et al. ELM—the eukaryotic linear motif resource in 2020. Nucleic Acids Res. 2020;48(D1):D296–D306. doi: 10.1093/nar/gkz1030 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Grant CE, Bailey TL, Noble WS. FIMO: scanning for occurrences of a given motif. Bioinformatics. 2011;27(7):1017–8. doi: 10.1093/bioinformatics/btr064 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Obenauer JC, Cantley LC, Yaffe MB. Scansite 2.0: proteome-wide prediction of cell signaling interactions using short sequence motifs. Nucleic Acids Res. 2003;31(13):3635–41. doi: 10.1093/nar/gkg584 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.Mosca R, Céol A, Stein A, Olivella R, Aloy P. 3did: a catalog of domain-based interactions of known three-dimensional structure. Nucleic Acids Res. 2014;42(D1):D374–D9. doi: 10.1093/nar/gkt887 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60.Berman H, Henrick K, Nakamura H. Announcing the worldwide Protein Data Bank. Nat Struct Mol Biol. 2003;10(12):980–. doi: 10.1038/nsb1203-980 [DOI] [PubMed] [Google Scholar]
  • 61.Vreven T, Moal IH, Vangone A, Pierce BG, Kastritis PL, Torchala M, et al. Updates to the Integrated Protein–Protein Interaction Benchmarks: Docking Benchmark Version 5 and Affinity Benchmark Version 2. J Mol Biol. 2015;427(19):3031–41. doi: 10.1016/j.jmb.2015.07.016 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62.La D, Kong M, Hoffman W, Choi YI, Kihara D. Predicting permanent and transient protein–protein interfaces. Proteins: Struct Funct Bioinform. 2013;81(5):805–18. 10.1002/prot.24235. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.Mintseris J, Weng Z. Atomic contact vectors in protein-protein recognition. Proteins: Struct Funct Bioinform. 2003;53(3):629–39. doi: 10.1002/prot.10432 [DOI] [PubMed] [Google Scholar]
  • 64.Ofran Y, Rost B. Analysing Six Types of Protein–Protein Interfaces. J Mol Biol. 2003;325(2):377–87. doi: 10.1016/s0022-2836(02)01223-8 [DOI] [PubMed] [Google Scholar]
  • 65.Block P, Paern J, Huellermeier E, Sanschagrin P, Sotriffer CA, Klebe G. Physicochemical descriptors to discriminate protein–protein interactions in permanent and transient complexes selected by means of machine learning algorithms. Proteins: Struct Funct Bioinform. 2006;65(3):607–22. doi: 10.1002/prot.21104 [DOI] [PubMed] [Google Scholar]
  • 66.Park SH, Reyes JA, Gilbert DR, Kim JW, Kim S. Prediction of protein-protein interaction types using association rule based classification. BMC Bioinformatics. 2009;10(1):36. doi: 10.1186/1471-2105-10-36 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 67.Bossi A, Lehner B. Tissue specificity and the human protein interaction network. Mol Syst Biol. 2009;5(1):260. doi: 10.1038/msb.2009.17 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68.Luck K, Kim D-K, Lambourne L, Spirohn K, Begg BE, Bian W, et al. A reference map of the human binary protein interactome. Nature. 2020;580(7803):402–8. doi: 10.1038/s41586-020-2188-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 69.Luck K, Sheynkman GM, Zhang I, Vidal M. Proteome-scale human interactomics. Trends Biochem Sci. 2017;42(5):342–54. doi: 10.1016/j.tibs.2017.02.006 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 70.Sahni N, Yi S, Zhong Q, Jailkhani N, Charloteaux B, Cusick ME, et al. Edgotype: a fundamental link between genotype and phenotype. Curr Opin Genet Dev. 2013;23(6):649–57. doi: 10.1016/j.gde.2013.11.002 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 71.Orchard S, Ammari M, Aranda B, Breuza L, Briganti L, Broackes-Carter F, et al. The MIntAct project—IntAct as a common curation platform for 11 molecular interaction databases. Nucleic Acids Res. 2014;42(D1):D358–D63. doi: 10.1093/nar/gkt1115 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 72.Rolland T, Taşan M, Charloteaux B, Pevzner Samuel J, Zhong Q, Sahni N, et al. A Proteome-Scale Map of the Human Interactome Network. Cell. 2014;159(5):1212–26. doi: 10.1016/j.cell.2014.10.050 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 73.Landrum MJ, Lee JM, Benson M, Brown G, Chao C, Chitipiralla S, et al. ClinVar: public archive of interpretations of clinically relevant variants. Nucleic Acids Res. 2016;44(D1):D862–D8. doi: 10.1093/nar/gkv1222 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 74.Sherry ST, Ward MH, Kholodov M, Baker J, Phan L, Smigielski EM, et al. dbSNP: the NCBI database of genetic variation. Nucleic Acids Res. 2001;29(1):308–11. doi: 10.1093/nar/29.1.308 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 75.Schymkowitz J, Borg J, Stricher F, Nys R, Rousseau F, Serrano L. The FoldX web server: an online force field. Nucleic Acids Res. 2005;33(suppl_2):W382–W8. doi: 10.1093/nar/gki387 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 76.Kryukov GV, Pennacchio LA, Sunyaev SR. Most Rare Missense Alleles Are Deleterious in Humans: Implications for Complex Disease and Association Studies. Am J Hum Genet. 2007;80(4):727–39. doi: 10.1086/513473 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 77.Barrett T, Wilhite SE, Ledoux P, Evangelista C, Kim IF, Tomashevsky M, et al. NCBI GEO: archive for functional genomics data sets—update. Nucleic Acids Res. 2013;41(D1):D991–D5. doi: 10.1093/nar/gks1193 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 78.Yates A, Akanni W, Amode MR, Barrell D, Billis K, Carvalho-Silva D, et al. Ensembl 2016. Nucleic Acids Res. 2016;44(D1):D710–D6. doi: 10.1093/nar/gkv1157 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 79.Forrest ARR, Kawaji H, Rehli M, Kenneth Baillie J, de Hoon MJL, Haberle V, et al. A promoter-level mammalian expression atlas. Nature. 2014;507(7493):462–70. doi: 10.1038/nature13182 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 80.Su AI, Wiltshire T, Batalov S, Lapp H, Ching KA, Block D, et al. A gene atlas of the mouse and human protein-encoding transcriptomes. Proc Natl Acad Sci USA. 2004;101(16):6062. doi: 10.1073/pnas.0400782101 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 81.Cui H, Srinivasan S, Korkin D. Enriching Human Interactome with Functional Mutations to Detect High-Impact Network Modules Underlying Complex Diseases. Genes. 2019;10(11):933. doi: 10.3390/genes10110933 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 82.Zhao N, Han JG, Shyu C-R, Korkin D. Determining Effects of Non-synonymous SNPs on Protein-Protein Interactions using Supervised and Semi-supervised Learning. PLoS Comp Biol. 2014;10(5):e1003592. doi: 10.1371/journal.pcbi.1003592 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 83.Geng C, Xue LC, Roel-Touris J, Bonvin AMJJ. Finding the ΔΔG spot: Are predictors of binding affinity changes upon mutations in protein–protein interactions ready for it? WIREs Comput Mol Sci. 2019;9(5):e1410. 10.1002/wcms.1410. [DOI] [Google Scholar]
  • 84.Xiong P, Zhang C, Zheng W, Zhang Y. BindProfX: Assessing Mutation-Induced Binding Affinity Change by Protein Interface Profiles with Pseudo-Counts. J Mol Biol. 2017;429(3):426–34. doi: 10.1016/j.jmb.2016.11.022 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 85.Rodrigues CHM, Myung Y, Pires DEV, Ascher DB. mCSM-PPI2: predicting the effects of mutations on protein–protein interactions. Nucleic Acids Res. 2019;47(W1):W338–W44. doi: 10.1093/nar/gkz383 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 86.Rodrigues CHM, Pires DEV, Ascher DB. DynaMut2: Assessing changes in stability and flexibility upon single and multiple point missense mutations. Protein Sci. 2021;30:60–9. doi: 10.1002/pro.3942 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 87.Gerasimavicius L, Liu X, Marsh JA. Identification of pathogenic missense mutations using protein stability predictors. Sci Rep. 2020;10(1):15387. doi: 10.1038/s41598-020-72404-w [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 88.Jankauskaitė J, Jiménez-García B, Dapkūnas J, Fernández-Recio J, Moal IH. SKEMPI 2.0: an updated benchmark of changes in protein–protein binding energy, kinetics and thermodynamics upon mutation. Bioinformatics. 2019;35(3):462–9. doi: 10.1093/bioinformatics/bty635 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 89.Landry Christian R, Levy Emmanuel D, Abd Rabbo D, Tarassov K, Michnick Stephen W. Extracting Insight from Noisy Cellular Networks. Cell. 2013;155(5):983–9. doi: 10.1016/j.cell.2013.11.003 [DOI] [PubMed] [Google Scholar]
  • 90.Wan C, Borgeson B, Phanse S, Tu F, Drew K, Clark G, et al. Panorama of ancient metazoan macromolecular complexes. Nature. 2015;525(7569):339–44. doi: 10.1038/nature14877 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 91.Hirsh AE, Fraser HB. Protein dispensability and rate of evolution. Nature. 2001;411(6841):1046–9. doi: 10.1038/35082561 [DOI] [PubMed] [Google Scholar]
  • 92.Pál C, Papp B, Hurst LD. Rate of evolution and gene dispensability. Nature. 2003;421(6922):496–7. doi: 10.1038/421496b [DOI] [PubMed] [Google Scholar]
  • 93.Hirsh AE, Fraser HB. Rate of evolution and gene dispensability. Nature. 2003;421(6922):497–8. doi: 10.1038/421497a [DOI] [PubMed] [Google Scholar]
  • 94.The UniProt Consortium. Activities at the Universal Protein Resource (UniProt). Nucleic Acids Res. 2014;42(D1):D191–D8. doi: 10.1093/nar/gkt1140 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 95.Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. Basic local alignment search tool. J Mol Biol. 1990;215(3):403–10. doi: 10.1016/S0022-2836(05)80360-2 [DOI] [PubMed] [Google Scholar]
  • 96.Webb B, Sali A. Comparative Protein Structure Modeling Using MODELLER. Curr Protoc Bioinformatics. 2016;54(1):5.6.1–5.6.37. doi: 10.1002/cpbi.3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 97.Bland M. An introduction to medical statistics. Oxford University Press; (UK). 2015. [Google Scholar]
PLoS Comput Biol. doi: 10.1371/journal.pcbi.1010013.r001

Decision Letter 0

Ozlem Keskin, Arne Elofsson

10 Sep 2021

Dear Dr. Xia,

Thank you very much for submitting your manuscript "Are transient protein-protein interactions more dispensable?" for consideration at PLOS Computational Biology.

As with all papers reviewed by the journal, your manuscript was reviewed by members of the editorial board and by several independent reviewers. In light of the reviews (below this email), we would like to invite the resubmission of a significantly-revised version that takes into account the reviewers' comments. 

We cannot make any decision about publication until we have seen the revised manuscript and your response to the reviewers' comments. Your revised manuscript is also likely to be sent to reviewers for further evaluation.

When you are ready to resubmit, please upload the following:

[1] A letter containing a detailed list of your responses to the review comments and a description of the changes you have made in the manuscript. Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

[2] Two versions of the revised manuscript: one with either highlights or tracked changes denoting where the text has been changed; the other a clean version (uploaded as the manuscript file).

Important additional instructions are given below your reviewer comments.

Please prepare and submit your revised manuscript within 60 days. If you anticipate any delay, please let us know the expected resubmission date by replying to this email. Please note that revised manuscripts received after the 60-day due date may require evaluation and peer review similar to newly submitted manuscripts.

Thank you again for your submission. We hope that our editorial process has been constructive so far, and we welcome your feedback at any time. Please don't hesitate to contact us if you have any questions or comments.

Sincerely,

Ozlem Keskin

Associate Editor

PLOS Computational Biology

Arne Elofsson

Deputy Editor

PLOS Computational Biology

***********************

Reviewer's Responses to Questions

Comments to the Authors:

Please note here if the review is uploaded as an attachment.

Reviewer #1: The review is uploaded as an attachment.

Reviewer #2: The authors present an analysis of the human interactome according to their dispensability and whether they’re transient or permanent. The dispensability is estimated using a Bayesian framework the authors introduced in previous work and based on mapping different types of SNPs onto the transcriptome. Transient vs. permanent is investigated in a number of different ways, including interaction strength, transience in time and space, etc.. Their main finding is that dispensability is at <20% and broadly similar for transient/permanent interactions. It is an interesting and counterintuitive finding (see below).

Overall, I think this is an interesting study, making use of fairly recently published large-scale data.

A number of points to be addressed:

1) The result that neither interaction strength nor permanence in time/space (or mutual exclusivity) is a factor for dispensability is quite counterintuitive and perhaps should be discussed more, in particular from an evolutionary standpoint. One would think that selection pressure would be lower on several kinds of transient interactions, e.g., those between protein domains from recently much expanded families and its partner, than on very old and tight protein complexes.

2) Also, if they were fully dispensable, there should also be fixed mutations (in chimp/mouse/etc.) that would get interfere with these interactions?

3) I can see that there is relatively little data on Kds for PPIs, but I’m not sure how reliable FoldX is for absolute Kds. Perhaps at least a bit of benchmarking would be in order?

4) Along similar lines, a ddG of 0.5 seems to be a fairly low cutoff. In particular if a dG of -25 is used as the cutoff for “strong”. Would it not mean that most “strong” interactions are hardly affected by some of the mutations? (going from, say, -30 kcal/mol to -29.5 kcal/mol)

Reviewer #3: Ghadie and Xua analyze the dispensable content among the transient protein-proteins interactions (PPIs) by comparing them to permanent PPIs. They map PPIs to the structural protein interactome and consider them together with the neutral and disease-associated mutations. The overarching aim of the study is stated as assessment of the importance of transient PPIs quantitatively. For this aim, authors collect data from several resources, including high-throughput PPI data, tissue specific expression data, time series data and integrates them to label interactions as transient and permanent. Additionally, they compare these two interaction types based on several characteristics. Although the study has important analysis addition, I have major concerns on the novelty that should be addressed in the manuscript. I have divided my comments into the sections to easily follow:

Introduction:

1. Introduction section has a very limited number of references despite there are many works studying transient interactions both computationally and experimentally. For example, between line numbers 53-65 authors have many strong statements, but none of them are supported with any citation. These statements need to be justified and properly supported with references.

2. “The question of how important transient PPIs…… ” sentence in line 62 sounds like still the importance of the transient PPIs not discovered. However, many studies either experimentally or computationally demonstrated that transient PPIs are an important component of signaling pathways, membrane interactions. Additionally, many experimental works are present and going on to quantitively measure the transient PPIs. I would suggest authors to include a review of experimental efforts and why computational approaches are important in this sense.

3. In the last paragraph of the Introduction, authors summarize their study. However, it is very long, and many technical details are included which are already there in the Results. This makes the paragraph very diffuse. Additionally, authors describe how they constructed the structural interactome between lines 85-90 which is the same procedure of a work by the same authors (Ghadie and Xua 2019, Nat Comm.). Repeating this part reduces the novelty aspect of the work. Is there any significant difference, update or improvement in the methodology in the construction of the structural interactome in this manuscript compared to the previous one? If yes, that aspect should be described. If no, I would suggest just citing their study and stating that the structural interactome in Ghadie and Xua 2019, Nat Comm. was used. I will have additional questions about the structural interactome in the other sections.

Results

4. The first two sections of the Results are a repetition of Ghadie and Xua 2019, Nat Comm. maybe with some dataset updates. My question is why the authors did not use the already available dataset that has been curated in their previous publication directly and label the transient and permanent PPIs but started the same pipeline from scratch and perform the same analysis to construct structural interactome, interface extraction and mutation mapping again. The data is already there. I understand that there might be some updates in PPIs and datasets but still it will be an addition to the already available one.

5. The work classifies the permanent and transient interactions based on the calculated dG values of FoldX. How good is FoldX in predicting transient and permanent interactions? Finding a ground truth dataset having already known permanent and transient interactions and calculating the precision, recall and other performance measures would support that the labelled permanent and transient interactions are at some accuracy or precise.

6. My previous comment is also valid for the overall pipeline. The authors have some assumptions based on tissue- or temporal- expression to classify transient and permanent interactions. However, there is no validation on a set of already known transient and permanent interactions. Applying their classification approach to a benchmark dataset and evaluate their performance would make a solid basis for their classification. A relevant paper to find a benchmark dataset might be PMC4084939. There are more articles I presume cataloging a benchmark dataset.

7. Authors collect the expression levels from GEO times series datasets and Illumina Body Map tissue expression dataset. More information needs to be added about these datasets. Are the samples from healthy people or from a patient? Are there the mutation profiles available for these samples in the same data sources? If yes, how much overlap is present between the sample mutation profiles and the mutations collected from dbSNP and ClinVar? The follow-up question would be how this information would affect their analysis, if available?

8. I think the novelty aspect of the study is hidden in the expression-based classification of permanent and transient interactions. However, interestingly, this aspect is not presented in the current manuscript as much as it deserves. Actually, Table 1 summarizes their overall results, but it is rather orphan in the text and not explained in detail in the Result section to give a detailed understanding about the results.

Other Comments

9. Discussion section reads like an extended abstract of the manuscript. It needs a detailed rewriting and discussing the results based on what available literature.

10. I strongly encourage the authors depositing all relevant codes to a repository and making available for the reproducibility of the study.

11. Author’s summary section repeats the Abstract. It is expected to provide a non-technical summary of the work. I suggest reconsidering this aspect and revising the summary.

**********

Have the authors made all data and (if applicable) computational code underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data and code underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data and code should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data or code —e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: None

Reviewer #3: No: The source codes are not provided.

**********

PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

Reviewer #3: No

Figure Files:

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org.

Data Requirements:

Please note that, as a condition of publication, PLOS' data policy requires that you make available all data used to draw the conclusions outlined in your manuscript. Data must be deposited in an appropriate repository, included within the body of the manuscript, or uploaded as supporting information. This includes all numerical values that were used to generate graphs, histograms etc.. For an example in PLOS Biology see here: http://www.plosbiology.org/article/info%3Adoi%2F10.1371%2Fjournal.pbio.1001908#s5.

Reproducibility:

To enhance the reproducibility of your results, we recommend that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option to publish peer-reviewed clinical study protocols. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols

Attachment

Submitted filename: PLOSCOMPUBIOLREVIEW.pdf

PLoS Comput Biol. doi: 10.1371/journal.pcbi.1010013.r003

Decision Letter 1

Ozlem Keskin, Arne Elofsson

11 Mar 2022

Dear Dr. Xia,

We are pleased to inform you that your manuscript 'Are transient protein-protein interactions more dispensable?' has been provisionally accepted for publication in PLOS Computational Biology.

Before your manuscript can be formally accepted you will need to complete some formatting changes, which you will receive in a follow up email. A member of our team will be in touch with a set of requests.

Please note that your manuscript will not be scheduled for publication until you have made the required changes, so a swift response is appreciated.

IMPORTANT: The editorial review process is now complete. PLOS will only permit corrections to spelling, formatting or significant scientific errors from this point onwards. Requests for major changes, or any which affect the scientific understanding of your work, will cause delays to the publication date of your manuscript.

Should you, your institution's press office or the journal office choose to press release your paper, you will automatically be opted out of early publication. We ask that you notify us now if you or your institution is planning to press release the article. All press must be co-ordinated with PLOS.

Thank you again for supporting Open Access publishing; we are looking forward to publishing your work in PLOS Computational Biology. 

Best regards,

Ozlem Keskin

Associate Editor

PLOS Computational Biology

Arne Elofsson

Deputy Editor

PLOS Computational Biology

***********************************************************

Reviewer's Responses to Questions

Comments to the Authors:

Please note here if the review is uploaded as an attachment.

Reviewer #1: Dear authors,

I would like to thank you for having taken all comments very seriously and addressing them carefully. I should also make amend for being a little rough on the data, forgetting too quickly how difficult experimental data are produced.

I have one last comment about the dispensable PPI based on the now clear definition, thank you. The dispensable PPI being those disturb by mutations at the interface and as a result disappearing from the interactomes with no impact on the fitness of the organism, could that define them as backup PPI (rather than dispensable in the sense of being useless for the fitness)? If their disappearance has no impact that could be because there is another PPI (or several other PPI) acting likewise. The sustainability of living systems is after all based on diversity of solutions, meaning backup /alternative ways. Maybe those dispensable PPI support the sustainability of the interactomes ie its future capacity to cope with perturbations, if removed the organism might become less and less sustainable, because it has a lower diversity.

Reviewer #2: THe authors addressed all of my comments.

**********

Have the authors made all data and (if applicable) computational code underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data and code underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data and code should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data or code —e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: None

**********

PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Claire Lesieur

Reviewer #2: No

PLoS Comput Biol. doi: 10.1371/journal.pcbi.1010013.r004

Acceptance letter

Ozlem Keskin, Arne Elofsson

28 Mar 2022

PCOMPBIOL-D-21-01091R1

Are transient protein-protein interactions more dispensable?

Dear Dr Xia,

I am pleased to inform you that your manuscript has been formally accepted for publication in PLOS Computational Biology. Your manuscript is now with our production department and you will be notified of the publication date in due course.

The corresponding author will soon be receiving a typeset proof for review, to ensure errors have not been introduced during production. Please review the PDF proof of your manuscript carefully, as this is the last chance to correct any errors. Please note that major changes, or those which affect the scientific understanding of the work, will likely cause delays to the publication date of your manuscript.

Soon after your final files are uploaded, unless you have opted out, the early version of your manuscript will be published online. The date of the early version will be your article's publication date. The final article will be published to the same URL, and all versions of the paper will be accessible to readers.

Thank you again for supporting PLOS Computational Biology and open-access publishing. We are looking forward to publishing your work!

With kind regards,

Livia Horvath

PLOS Computational Biology | Carlyle House, Carlyle Road, Cambridge CB4 3DN | United Kingdom ploscompbiol@plos.org | Phone +44 (0) 1223-442824 | ploscompbiol.org | @PLOSCompBiol

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Data. The human structural interactome.

    PPIs in the human structural interactome annotated with interface residue positions on canonical protein sequences from UniProt. (A) Y2H-SI. (B) Lit-SI.

    (XLSX)

    S2 Data. Edgetic PPI disruptions and mutation edgotypes.

    (A) Common mutations in Y2H-SI. (B) Disease mutations in Y2H-SI. (C) Common mutations in Lit-SI. (D) Disease mutations in Lit-SI.

    (XLSX)

    S3 Data. PPI change in binding free energy.

    PPI change in binding free energy (ΔΔG) upon mutation calculated on PPI structural models. (A) Common mutations in Y2H-SI. (B) Disease mutations in Y2H-SI. (C) Common mutations in Lit-SI. (D) Disease mutations in Lit-SI.

    (XLSX)

    S4 Data. PPI binding free energy.

    PPI binding free energy (ΔG) calculated on PPI structural templates from PDB.. (A) Y2H-SI. (B) Lit-SI.

    (XLSX)

    S5 Data. PPI classifications.

    (A) Y2H-SI. (B) Lit-SI.

    (XLSX)

    S6 Data. Gene expression sample information.

    (A) Sample counts and time points for all 63 datasets from GEO. (B) Names of the 16 tissues in the Illumina Body Map 2.0 dataset. (C) Names of the 183 tissue samples in the Fantom5 dataset.

    (XLSX)

    S7 Data. Co-expression of interaction partners.

    (A) Time-course co-expression in 63 GEO datasets for PPIs in Y2H-SI. (B) Time-course co-expression in 63 GEO datasets for PPIs in Lit-SI. (C) Tissue co-expression based on Illumina Body Map and Fantom5 data for PPIs in Y2H-SI. (D) Tissue co-expression based on Illumina Body Map and Fantom5 data for PPIs in Lit-SI.

    (XLSX)

    S8 Data. Time-course abundance of interaction partners.

    Difference in the log10 of time-course expression levels for interaction partners in the human structural interactome. (A) Expression difference at each time point in 63 GEO datasets for PPIs in Y2H-SI. (B) Expression difference at each time point in 63 GEO datasets for PPIs in Lit-SI.

    (XLSX)

    S9 Data. Tissue-based abundance of interaction partners.

    Difference in the log10 of tissue-based expression levels for interaction partners in the human structural interactome. (A) Expression difference among 16 tissues from Illumina Body Map for PPIs in Y2H-SI. (B) Expression difference among 16 tissues from Illumina Body Map for PPIs in Lit-SI. (C) Expression difference among 183 tissue samples from Fantom5 for PPIs in Y2H-SI. (D) Expression difference among 183 tissues samples from Fantom5 for PPIs in Lit-SI.

    (XLSX)

    S10 Data. Mutually exclusive and simultaneously possible PPIs.

    (A) Y2H-SI. (B) Lit-SI.

    (XLSX)

    S1 Text

    Fig A in S1 Text. Distribution of PPI transient classifications across multiple properties. Distribution of the number of times a PPI was classified as transient based on 8 different structural and biophysical measurements: PPI strength, transience in time (based on gene expression levels), transience in space (based on gene expression and promotor activity levels), stoichiometry in time (based on gene expression levels), stoichiometry in space (based on gene expression and promotor activity levels), and number of mutually exclusive PPIs.

    Fig B in S1 Text. Change in PPI binding free energy upon mutation. Change in PPI binding free energy (ΔΔG) distribution for all disease and common non-disease interfacial mutations in both structural interactomes Y2H-SI and Lit-SI. ΔΔG values were calculated using FoldX.

    Table A in S1 Text. Performance of predictions of temporally transient and permanent PPIs. Performance measures for predicting temporally transient PPIs and temporally permanent PPIs in human when benchmarked against experimental data combined from La et al. (2013) and Mintseris and Weng (2003).

    Table B in S1 Text. Dispensable content derived from different binding ΔΔG cut-offs. Dispensable content among weak and strong PPIs calculated using different binding ΔΔG cut-offs for predicting edgetic disruptions of PPIs in the two human structural interactomes Y2H-SI and Lit-SI.

    Table C in S1 Text. Edgetic mutation data derived from experiments. Number of common mutations and disease mutations in the experimental data of Sahni et al. 2015 that edgetically disrupt transient and permanent PPIs as defined by different biophysical and spatiotemporal properties. PPI disruptions by mutations were obtained from experiments of Sahni et al. 2015. PPI classifications were determined computationally.

    Table D in S1 Text. Dispensable content among transient and permanent PPIs in experiments. Edgotype probabilities for neutral and mildly deleterious mutations in the experimental data of Sahni et al. 2015 calculated among transient and permanent PPIs directly from Table C, assuming that common mutations are effectively neutral (N) and that disease mutations are mildly deleterious (M) on average. The resulting dispensable contents P(N|T) and P(N|P) among both transient (T) and permanent (P) PPIs were calculated using Bayes’ theorem. Columns represent the following, P(T|N): probability (%) for neutral mutations (N) to edgetically disrupt transient PPIs (T), P(T|M): probability (%) for mildly deleterious mutations (M) to edgetically disrupt transient PPIs (T), P(N|T): dispensable content among transient PPIs defined as the probability (%) for transient PPIs to be effectively neutral upon disruption, P(P|N): probability (%) for neutral mutations (N) to edgetically disrupt permanent PPIs (P), P(P|M): probability (%) for mildly deleterious mutations (M) to edgetically disrupt permanent PPIs (P), P(N|P): dispensable content among permanent PPIs defined as the probability (%) for permanent PPIs to be effectively neutral upon disruption. CI: 95% confidence interval (%) for dispensable contents P(N|T) and P(N|P). PPI disruptions by mutations were obtained from experiments of Sahni et al. 2015. PPI classifications were determined computationally.

    Table E in S1 Text. Mono-edgetic mutation data obtained from predictions. Number of common mutations and disease mutations that edgetically disrupt a single transient PPI or permanent PPI defined by different structural, biophysical and spatiotemporal properties in the two human structural interactomes Y2H-SI and Lit-SI.

    Table F in S1 Text. Dispensable content among transient and permanent PPIs based on mono-edgetic mutations. Edgotype probabilities for neutral and mildly deleterious mutations calculated directly from edgotype numbers in Table E, assuming that common mutations are effectively neutral (N) and that disease mutations are mildly deleterious (M) on average. The resulting dispensable contents P(N|T) and P(N|P) among both transient (T) and permanent (P) PPIs were calculated using Bayes’ theorem. Columns represent the following, SI: structural interactome, P(T|N): probability (%) for neutral mutations (N) to edgetically disrupt a single transient PPI (T), P(T|M): probability (%) for mildly deleterious mutations (M) to edgetically disrupt a single transient PPI (T), P(N|T): dispensable content among transient PPIs defined as the probability (%) for transient PPIs to be effectively neutral upon disruption, P(P|N): probability (%) for neutral mutations (N) to edgetically disrupt a single permanent PPI (P), P(P|M): probability (%) for mildly deleterious mutations (M) to edgetically disrupt a single permanent PPI (P), P(N|P): dispensable content among permanent PPIs defined as the probability (%) for permanent PPIs to be effectively neutral upon disruption.

    Table G in S1 Text. Confidence intervals for dispensable content based on mono-edgetic mutations. 95% confidence intervals for estimates of dispensable content P(N|T) and P(N|P) in Table F based on mono-edgetic mutations.

    (PDF)

    Attachment

    Submitted filename: PLOSCOMPUBIOLREVIEW.pdf

    Attachment

    Submitted filename: Response_to_reviewers.pdf

    Data Availability Statement

    The source data underlying all figures are included in this article and its supplementary data files. Code that was used to build the human structural interactome is available at the following GitHub repository: https://github.com/MohamedGhadie/build_structural_interactome. Code that was used to map mutations onto the human structural interactome and calculate dispensable content among transient PPIs and permanent PPIs is available at the following GitHub repository: https://github.com/MohamedGhadie/dispensable_transient_ppis.


    Articles from PLoS Computational Biology are provided here courtesy of PLOS

    RESOURCES